Treatment of ciliopathies
Patent Information
- Application Number
- JP2024060297
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-02-14
- Filing Date
- 2024-04-03
- Publication Date
- 2024-11-01
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for ciliopathies, such as primary ciliary dyskinesia (PCD), are not standardized and ineffective, as they are often extrapolated from cystic fibrosis and do not specifically address the ciliary motility defects caused by genetic mutations in proteins essential for cilia function.
A pharmaceutical composition comprising polyribonucleotides that encode functional versions of proteins associated with ciliary structure and function, administered during respiratory inflammation to restore proper ciliary function by transfecting epithelial cells, particularly targeting basal cells before they reach the epithelial surface.
The method effectively restores ciliary function, improving mucus clearance and reducing symptoms of ciliopathies by administering polyribonucleotides that encode functional proteins, such as CCDC40 and CCDC39, during respiratory inflammation to target inaccessible basal cells.
Smart Images

Figure 2024096766000001 
Figure 2024096766000002
Abstract
Description
[Technical field]
[0001] The present invention relates to a polyribonucleotide for use in the treatment of a ciliopathic disease in a subject suffering from a ciliopathic disease. A pharmaceutical composition comprising a nucleotide, the polyribonucleotide comprising a nucleotide sequence that is capable of determining whether a defect is present in the pilus. said pharmaceutical composition comprising a polypeptide encoding a functional version of a protein associated with said disease; Administration to the respiratory system of an elephant occurs when the subject exhibits inflammation of the respiratory system (eff The present invention further relates to a pharmaceutical composition comprising a ciliary form of polyribonucleotide. The method of claim 1, wherein the polyribonucleotide is a polypeptide related to ciliary formation. The present invention relates to methods for encoding proteins associated with and / or required for the same. [Background technology]
[0002] Oxygen is essential for cellular energy supply and is therefore essential for many multicellular organisms. In mammals, oxygen in the air is absorbed by the respiratory organs. They can enter the organism through the respiratory system, which refers to the nasal passages, throat, larynx, These include the trachea, bronchi, and lungs, in the latter of which gases from the environment enter the internal blood circulation. It is exchanged with the gases contained in it, which transports oxygen from the lungs to the cells in different parts of the organism. However, in addition to the oxygen required, pollutants, disease-causing substances and pathogens (e.g. Other components, such as irritants present in the air, including viruses and bacteria, may also affect breathing. It can enter the organism via the respiratory system, thus triggering a cough reaction to expel the irritant from the respiratory system. For excretion, irritants are absorbed into the epithelial cells of the respiratory system. in a viscous mucus that is secreted by the epithelium and then transported across the epithelial surface by ciliated cells. is embedded in.
[0003] Ciliated cells transport mucus and irritants across epithelial surfaces by the synchronous beating of hyperkinetic motile cilia. The ciliary body is a membrane-bound tubular structure that transports blood from the epithelial surface to the environment. Within the cell, the axoneme of the cilia is attached via an anchoring structure. The axoneme is a central bundle of microtubules, which is bounded by nine outer doublet microtubules. The tubes surround a central pair of singlet microtubules (i.e., respiratory cilia). The bullet microtubules and the central pair of microtubules are connected by radial spokes. Each bullet microtubule is composed of an A-tubule and a B-tubule, and the doublet is composed of nexin-dimers. The inner and outer dynein arms are bound circumferentially by the dynein regulatory complex. These dynein arms are connected to the A-tubules. proteins that cause the bending and thus beating of the cilia (e.g., Lod ish et al, 2000, Molecular Cell Biology, 4 th edition, New York: W. H. Freeman, S. (See section 19.4.) Using the model Trypanosoma brucei, Studies of ciliary body structure have shown that some of these structural components exhibit rapid turnover. The skeletal components of the radial spokes, central pair and lateral dynein arms form ciliary structures during development. showed that the nucleus is mainly integrated in the distal end of the nucleus (Vincensini et al., iol Cell, 2018, 110:1-15).
[0004] Synchronized beating of ciliated cells is essential for the transport of fluid across epithelial surfaces, and therefore the structure of the cilia Disturbances can cause serious disorders. Reduced pulsatility and / or asynchrony. Motility defects including amplitude and / or frequency can include, for example, a reduction or loss of dynein arms, Disorganization of microtubule arrangement, including mislocalization, and the total number of microtubules per axon As far as is known, these functional axonemes can result from a number of different alterations, as well as combinations thereof. Elemental changes are caused by underlying genetic defects. These are primarily the same as those mentioned above. This is due to changes in the sequences of genes that code for axonemal components, including the and then translated into a protein, The DNA sequence of each protein affects its synthesis in terms of quantity and functionality. Ciliopathies, i.e. ciliopathies caused by changes in the base sequence, are inherited. , and is associated with impaired ciliary motility at all developmental stages, including embryonic and neonatal stages. Therefore, cilia disorders can have serious consequences for the organism.
[0005] A well-known example of a ciliopathic disorder is primary ciliopathia, a progressive disease that is often associated with decreased lung function. Thus, the increase in frequency increases mucus clearance. and in severe cases, lung transplantation, long-term treatment, including chest percussion and postural drainage, In addition, PCD patients often suffer from subfertility, hydrocephalus and body asymmetry. i.e., left-right axis, defects, and retinal and / or neurological problems, as well as pulmonary and / or or suffer from recurrent infections in the ears. However, the severity of most ciliopathies is Regardless, a standardized and effective strategy for treating ciliary diseases such as PCD has not been available to date. Current treatments are extrapolated from cystic fibrosis, for example, and are largely In this case, the drug has not been tested for the specific ciliopathies it is intended to treat, such as PCD. Therefore, subjects suffering from ciliopathies such as PCD can be effectively treated. It is necessary to have a solution at hand. Summary of the Invention [Problem to be solved by the invention]
[0006] The present application provides embodiments as set forth in the claims, which allow the development of cilia such as PCDs. The present invention addresses the need to restore ciliary function in diseased subjects. [Means for solving the problem]
[0007] In particular, the present invention relates to a method for treating a ciliopathic disease in a subject suffering from a ciliopathic disease. A pharmaceutical composition comprising a polyribonucleotide, the polyribonucleotide comprising a pre-deleted polyribonucleotide. The pharmaceutical composition further comprises a polypeptide encoding a functional version of the protein associated with said ciliopathies. Administration to the subject's respiratory system occurs when the subject exhibits inflammation of the respiratory system (e.g., effected), and relates to pharmaceutical compositions. [Brief description of the drawings]
[0008] [Figure 1]Figure 1: Translation efficiency of CCDC40 mRNA. 2 / 1.4 / 0.3 / 0.2 / 0.05x10^6 HEK293 cells were seeded in 6-well plates. Seedling cells were transfected with different CCDC40 constructs (ETH031T06-T10, 2.5μg / 9.5cm2) for 24 h using Lipofectamine2000. Cell lysis was performed 6, 24, 48, 72 and 144 h after transfection. 50μg of total protein lysates were analyzed by SDS-PAGE and Western blot. CCDC40 was detected using anti-CCDC40 antibody (HPA022974) from Atlas Antibodies (1:2000) and GAPDH served as a loading control. GFP served as a transfection control. [Diagram 2] Figure 2: Translation efficiency of CCDC40 mRNA constructs in BEAS-2B, RPMI2650, and HEK293 cells: 2x10^6 HEK293, 7.5x10^5 BEAS-2B, and 5x10^5 RPMI 2650 cells were seeded in 6-well plates. 24 h after seeding, cells were transfected with different CCDC40 constructs (2.5μg / 9.5cm2) using Lipofectamine2000. Cell lysis was performed 6 h after transfection. Protein lysates were analyzed by SDS-PAGE and Western blot (HEK293: 50μg, RPMI 2650: 20μg, BEAS-2B: 30μg of total lysate) and CCDC40 was detected using anti-CCDC40 antibody (HPA022974) from Atlas Antibodies (1:2000). [Diagram 3]Figure 3: High-speed video microscopy (HSVM) results after LF92 / CCDC40 transfection. Patient-derived ALI cultures were transfected every other day with 3 μg of LF92 / CCDC40. Videos (20 per insert) were taken before transfection and every 24 h after transfection and the CFB (ciliary beating frequency) was calculated using SAVA (Sisson-Ammons video analysis) software. A total of 16 transfections (1 month) were performed. Measurements were performed at 37 °C with 40x magnification. The mean value of the ciliary beating frequency measurements is calculated (total field analysis, WFA). [Figure 4] Figure 4: Mucociliary clearance (MCC) is shown as Z-projection and polar graph. CCDC40 patient ALI cultures were transfected with CCDC40 mRNA / LF92 at a concentration of 3 μg / insert for 18 days by airlift. ALI cultures were maintained in medium G for the duration of the experiment. Transfections (TF) were performed once a week for 4 weeks (=4xTF). Mucociliary clearance (MCC) was measured at 20x magnification using 0.5 μm fluorescent beads. 30 videos of different areas were taken and analyzed with the Polargraph software from Nikon 1 week after the last TF. One exemplary picture is shown. [Diagram 5]Figure 5: Mucociliary clearance (MCC) shown as Z-projection (top left) and polar graph (top right) for tdTomato and polar graphs of healthy (bottom right) controls. Top row: Cells from a patient with a CCDC40 mutation in ALI culture were transfected with tdTomato mRNA / LF111 at a concentration of 3 µg / insert 18 days after airlift. ALI cultures were maintained in medium G for the duration of the experiment. Transfections (TF) were performed once a week for 4 weeks (=4xTF). Mucociliary clearance (MCC) was measured at 30x magnification using 0.5 µm fluorescent beads. 20 videos of different areas were taken and analyzed with Polargraph software from Nikon 1 week after the last TF. One exemplary video was shown. Bottom right: Particle tracking of a healthy WT ALI culture. MCC was measured at 20x magnification using 0.5 µm fluorescent beads. Twenty videos of different areas were taken and analyzed with the Polargraph software from Nikon one week after the last TF. One exemplary image and two analyzed ROIs are shown. [Figure 6] Figure 6: Cells from patients with CCDC40 mutations in ALI cultures were transfected with either tdTomato mRNA / LF111 or CCDC40 mRNA / LF92 at a dose of 3 µg / insert for 18 d at airlift. ALI cultures were maintained in medium G for the duration of the experiment. Transfections (TF) were performed once a week for 4 weeks (=4xTF). As control, WT ALI from healthy nasal brushes were used. ALI membranes treated with CCDC40 mRNA and tdTomato mRNA were sectioned at 20 µm and stained with anti-GAS8 (red), anti-acetylated tubulin (green) and DAPI (blue). Photographs were taken with a confocal microscope. One exemplary image is shown. Scale bar represents 10 µm. [Figure 7]Figure 7: Cells from patients with CCDC40 mutations in ALI cultures were transfected with either tdTomato mRNA / LF111 or CCDC40 mRNA / LF92 at a dose of 3 μg / insert, 18 d after airlift. ALI cultures were maintained in medium G for the duration of the experiment. Transfections (TF) were performed once a week for 4 weeks (=4xTF). As control, ALI from healthy controls were used. ALI membranes treated with CCDC40 mRNA and tdTomato mRNA were sectioned at 20 μm and stained with anti-DNALI1 (red), anti-acetylated tubulin (green) and DAPI (blue). Photographs were taken with a confocal microscope. One exemplary image is shown. Scale bar represents 10 μm. [Figure 8] Figure 8: Cells from patients with CCDC40 mutations in ALI cultures were transfected with either tdTomato mRNA / LF111 or CCDC40 mRNA / LF92 at a dose of 3 μg / insert for 18 d at air lift. ALI cultures were maintained in medium G for the duration of the experiment. Transfections (TF) were performed once a week for 4 weeks (=4xTF). As control, ALI from healthy controls were used. ALI membranes treated with CCDC40 mRNA and tdTomato mRNA were sectioned at 20 μm and stained with anti-CCDC39 (1:200, red), anti-acetylated tubulin (1:10.000, green) and DAPI (blue). Pictures were taken with a confocal microscope. One exemplary image is shown. Magnification 40x. [Figure 9]Figure 9: CCDC39 protein (110 kDa) expression in HEK-293 and BEAS-2B, 6 and 24 hours after transfection. 1.4x10^5 HEK-293 cells and 3.5x10^5 BEAS-2B cells were seeded in 6 well plates and transfected with CCDC39-RNA (ETH047T02, minimal 5'UTR, Lipofectamine MessengerMax; ratio 1:1.5). After 6 and 24 hours, cells were lysed with M-PER and Triton® X-100 buffer. 50 μg of protein lysate was used for Western blot analysis. As controls, lysates of non-transfected (UT) and EGFP-transfected cells were used. High dose = 0.5 μg / cm2, low dose = 0.25 μg / cm2. [Figure 10] Figure 10: CCDC39 protein (110 kDa) expression in untreated ALI cultures. Two inserts were extracted using the axonal extraction protocol. 30, 10 and 5 μL of protein lysate were used for Western blot analysis. Active Area: Insert 39.9 = 71.25%, Insert 41.2 = 59.88% [Figure 11] Figure 11: CCDC39 protein (110 kDa) expression in 16HBE14 after proteasome inhibitor treatment. 6.0x10^5x16HBE14ocells were seeded in 6-well plates and transfected with CCDC39-RNA (Lipofectamine MessengerMax; ratio 1:1.5). After 6 h, cells were lysed with M-PER buffer. 20 μg of protein lysate was used for Western blot analysis. As controls, lysates of non-transfected (UT) and EGFP-transfected cells were used. High dose = 0.5 μg / cm2, low dose = 0.25 μg / cm2. RNA: ETH047T02: minimal 5'UTR, ETH047T03: TISU, ETH047T04: CYBA, ETH047T05: SP30. [Figure 12]Figure 12: CCDC39 protein (110 kDa) expression upon 16HBE14oafter treatment with proteasome inhibitors. 6.0x10^5 16HBE14ocells were seeded in 6-well plates and transfected with CCDC39-RNA (ETH047T03, TISU 5'UTR, Lipofectamine Messenger Max; ratio 1:1.5). After 24 hours, cells were lysed with M-PER buffer. 20 μg of protein lysate was used for Western blot analysis. As controls, lysates of non-transfected (UT) and EGFP-transfected cells were used. High dose=0.5 μg / cm2, low dose=0.25 μg / cm2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] The present invention shows that a specific protein in a protein complex of cells (cilia) is defective, and that the defect resulting in loss of proper cilia function) by the use of a polypeptide encoding a functional version of the protein. Transfection with ribonucleotides actually restores proper cilia function. However, to achieve this effect, ciliated cells It was also found that the transfection of β-lactams must occur at an early stage of differentiation. The precursor cells of the epithelial cells that produce cilia, i.e., basal cells, are located deeper and lower within the epithelium and The surface of the cells is not exposed and therefore inaccessible for transfection via the airway system. According to the present invention, the administration of polyribonucleotides Transfection of epithelial cells is performed when subjects with ciliopathies exhibit respiratory inflammation. During respiratory inflammation, the airway epithelium produces progenitor cells of ciliated cells, i.e. cells that have yet to form cilia. Lesions and wounds that allow access to uninitiated basal cells are shown. These cells are then pretreated with polyribonucleotides as described above that express functional versions of the proteins. Transfecting these cells can lead to substantial alleviation of the respective symptoms. The present invention provides a method for producing a cell that forms functional cilia or at least partially functional cilia. do.
[0010] In the context of the present invention, the term "ciliopathies" refers to diseases associated with defects in ciliated cells and / or Thus, trichiasis refers to a disease characterized by a ciliary fixed structure, a ciliary structure, Disorders of ciliary structure, including basal bodies whose structures are anchored intracellularly, and / or ciliary function Examples of ciliopathies include PCD, Bardet-Biedl syndrome, Simpson- Golabi-Behmel syndrome (type 2), leber congenital amaurosis, nephronophthisis, head ectodermal dysplasia (Sensenbrenner) (e.g., Mitchi son et al., 2017, Ultrastructural Pathol (see Ogy, 41(6):415-427).
[0011] As used herein, the term "ciliopathies" refers to genetic defects in a subject's DNA, e.g. , refers to ciliopathy caused by chromosomal or mitochondrial DNA. The genetic defect may be caused by a mutation and may include the loss, addition or exchange of a sequence portion. Examples include copy number variants, presence / absence variants, deletions (full or partial), insertions, and missense variants. , nonsense mutations, splice site mutations, or a combination thereof. Such changes can be due to changes in the availability of the encoded protein (e.g., This may result in a protein having a reduced abundance, loss or altered function.
[0012] In a preferred embodiment, the term "ciliopathies" refers to those related to motile ciliary dyskinesia (PCD). PCD is a rare disease caused by the dysfunction of motile cilia. PCD is heterogeneous at the genetic, functional and ultrastructural levels. The subjects are suffering from recurrent nasal congestion, sinus infections, ear infections, infertility such as situs inversus and ectopic pregnancy, etc. At the molecular level, PCD is most often seen in the respiratory tract, where cilia are located, and / or hydrocephalus. These are associated with abnormalities in the structure, function, and biogenesis of dynein. These include the absence or shortening of the nucleus, complexes, radial spokes or nexin links. The abnormalities, and therefore the ciliary motility defects associated with PCD, encode the respective components. Mutations in genes that affect the "B", caused by mutations, account for at least 1% and less than 1% of PCD cases, respectively. It refers to genes with pathogenic variants that are presumed to account for 100% of all cases (Zariwala et al. l., GeneReviews(R), 2007, updated 20 15, Primary Ciliary Dyskinesia, editors Adam et al., Seattle (WA): University of (Washington, Seattle; see 1993-2018).
[0013] The polyribonucleotides contained in the pharmaceutical composition according to the invention are therefore preferably A polyribonucleotide that can be translated into a functional version of a protein listed in Table 1. be.
[0014] More preferably, the polyribonucleotide contained in the pharmaceutical composition of the present invention is DNAH5 , DNAH11, CCDC39, DNAI1, CCDC40, CCDC103, SPAG 1, ZMYND10, ARMC4, CCDC151, DNAI2, RSPH1, CCDC 114, RSPH4A, DNAAF1(LRC50), DNAAF2(KTU), and A mRNA that can be translated into a functional version of a protein selected from the group consisting of LRRC6. It is NA.
[0015] [Table 1]
[0016] In some embodiments of any of the above or other aspects and embodiments of the present disclosure, The polyribonucleotide or modified polyribonucleotide is selected from the group consisting of SEQ ID NOs: 1 and 5 to 11. At least 85% of one or more of the sequences (e.g., sequences set forth in SEQ ID NOs: 1 or 5 to 11) and at least at least 90%, at least 92% or at least 95% identical (e.g., at least 95 , 96, 97, 98, 99 or 100% identical). In the form, the polyribonucleotide may be present at any such level and / or at any such level as described herein. or a type of modification selected from the group consisting of: In certain embodiments, the percent identity of a polyribonucleotide is is measured only for the CCDC40 coding sequence portion of SEQ ID NO: 1 or 5 to 11 ( For example, when calculating percent identity, the UTRs, other non-coding sequences and GFP or (Epitope tags are not considered in this case.) In certain embodiments of any of the above, such Such polyribonucleotides (or modified polyribonucleotides) are functional CCDC40 Encodes proteins.
[0017] In some embodiments of any of the above or other aspects and embodiments of the present disclosure, The polyribonucleotide or modified polyribonucleotide is represented by SEQ ID NO: 2 or 12 to 14. At least 85% of one or more of the sequences (e.g., sequences set forth in SEQ ID NO: 2 or 12 to 14) and at least 90%, at least 92%, or at least 95% identical (e.g., at least 95, 96, 97, 98, 99 or 100% identical). In embodiments, the polyribonucleotide is at any such level and and / or type of modification selected from the group consisting of: In certain embodiments, the percent identity of a polyribonucleotide is The sex is measured only with respect to the CCDC39 coding sequence portion of SEQ ID NO: 2 or 12-14. (For example, when calculating percent identity, take into account UTRs, other non-coding sequences and the GFP tag.) In certain embodiments of any of the above, Such polyribonucleotides (or modified polyribonucleotides) are functional CCDs. It encodes the C39 protein.
[0018] In some embodiments of any of the above or other aspects and embodiments of the present disclosure, The polyribonucleotide or modified polyribonucleotide is SEQ ID NO:4 (e.g., SEQ ID NO:4 ) and at least 85%, at least 90%, at least 92%, or at least 95% identical (e.g., at least 95, 96, 97, 98, 99 or In some embodiments, the polyribonucleotide comprises a primary sequence that is 100% identical to the primary sequence of the polyribonucleotide. is selected from any such level and / or type described herein. The present invention relates to a method for the preparation of modified polyribonucleotides having a specific level and / or type. The percent identity of the polyribonucleotide is determined by the MCIDAS code of SEQ ID NO:4. Only sequence parts are measured (e.g., when calculating percent identity, UTRs, (Other non-coding sequences and GFP or epitope tags are not considered.) Any of the above In certain embodiments, such polyribonucleotides (or modified polyribonucleoside)s are tide) encodes a functional MCIDAS protein.
[0019] In certain embodiments, the present disclosure provides a pharmaceutical composition comprising any of the aforementioned polyribonucleotides. Furthermore, any such polyribonucleotide (or pharmaceutical composition) is , may be used in any of the methods described herein.
[0020] In one embodiment of a pharmaceutical composition comprising a polyribonucleotide for use in treating a ciliopathic disease, The ciliopathies are caused by the coiled-coil domain-containing 40 (CCDC40; human mRNA and For the CCDC40 protein sequence, see, for example, the NCBI reference sequence NM_0 17950.4 and NP_060420.2) protein deficiency or coiling Coiled coil domain-containing 39 (CCDC39; human mRNA and protein CCDC39 For sequences, refer to NCBI reference sequences NM_181426.2 and NP_852, respectively. See 091.1) Related to protein deficiencies.
[0021] CCDC40 and CCDC39 form a complex located between the radial spokes and the A-tubule. Defective versions of the CCDC40 or CCDC39 proteins are constructed by the CCDC40 gene, or mutations in the CCDC39 gene, including insertions, deletions, nonsense and splice site mutations In particular, the CCDC40 protein may be caused by Deletions at position 248 and TGT insertions between positions 2824 and 2825 are quite frequent. It is believed that the deletion of CCDC40 or CCDC39 results in defects in axon structure ( For example, absence or eccentricity of the central pair, abnormal radial spokes and nexin linkages, dynein This results in abnormal assembly of regulatory complexes and / or a decrease in the inner dynein arm. Therefore, the polyribonucleotide contained in the pharmaceutical composition according to the invention is preferably mRNA that can be translated into functional versions of CDC40 and / or CCDC39. Proteins related to ciliogenesis, and genes and molecular pathways related to ciliopathies For more information, see, for example, the review article by Reiter and Leroux ( eiter and Leroux, 2017, Nat Rev Mol Cell Biol, 18(9):533-547).
[0022] The pharmaceutical composition of the present invention is administered to a subject suffering from a ciliopathic disease. A subject suffering from an inflammatory bowel disease may also be referred to as a patient. A patient may have mucus and bacteria in the airways. exhibit abnormal ciliary structure and / or function, and / or biosynthetic defects, resulting in the retention of The diagnosis of ciliopathies in a given subject may be made using, for example, the method described in Goutaki et al. al. (Goutaki et al., 2016, Eur Respir J, For example, as outlined in the above (48(4):1081-1095) The method may be based on clinical findings, molecular analysis and / or hair ultrastructural analysis of the specimen.
[0023] In the context of the present invention, the term "polyribonucleotide" refers to any combination of adenosine, guanosine, and ribonucleotides. Consisting of ribozyme, cytidine, and / or uridine residues (modified or unmodified, see below) As used herein, "polyribonucleic acid encoding a protein" refers to a single-stranded sequence. The term "ribonucleotide" refers to a polyribonucleotide that contains a coding region that encodes a protein. i.e., a polyribonucleotide that can be translated into an amino acid sequence. Therefore, in the context of the present invention, the term "protein-encoding polyribonucleotide" is used. The term preferably refers to mRNA, which when entered into a cell is suitable for expression of a protein. "ribonucleotide" refers to any polyribonucleotide molecule that is capable of being translated into a protein. Then it should be understood.
[0024] As used herein, the term "protein" refers to any type of amino acid sequence, i.e. Each of these includes a chain of two or more amino acids linked together through peptide bonds. The term "protein" as used in this context refers to any amino acid sequence of interest. Preferably, the encoded amino acid sequence is at least 5 amino acids long, more preferably at least At least 10 amino acids, even more preferably at least 50, 100, 200 or 5 The term "protein" therefore refers to short peptides and polypeptides. Deletion or modification of a protein with respect to the function of the encoded protein. There are no limitations, except that the term "associated with" refers to a ciliopathy. The term encompasses the terms "causes," "associates," and / or "enhances." It is intended that.
[0025] As used herein, the term "a protein having a defect therein" refers to a "defective protein" or refers to a "deleted version of a protein" and therefore compared to a functional version of said protein. However, the term also refers to synthetic complete or altered versions of proteins. The protein has a partial lack and therefore availability in the cell. In either case, the defect in the protein version is a defect in the natural This results in a version of the protein that is unable to fulfill the function of
[0026] A version of a protein that fulfills its native function is referred to herein as a "functional protein." The defective proteins and functional versions of the proteins are called are encoded by the same DNA sequence, but the deletion does not result in a change in the DNA sequence , and therefore there is no mutation in the DNA sequence.
[0027] Therefore, in the context of the present invention, a "functional protein" is preferably an A-tubulin. B-tubules, or the nexin-dynein regulatory complex, or the radial sporulation They are building blocks of the dynein cDNA, the inner dynein arm, and / or the outer dynein arm.
[0028] Thus, the term "polyribonucleotides, the deficiency of which is associated with said ciliopathies, The term "encodes a functional version of the cilia, axon anchoring structure or basal mRNAs that code for functional proteins that are involved in the structural organization of the body and perform their intended functions A. Thus, the polyribonucleotide according to the invention is preferably a functional protein. This refers to the mRNA that encodes the protein, the presence of which is in the cells of a subject suffering from ciliopathies. of said ciliopathies associated with a defect in said protein encoded by a DNA sequence of a cell. Necessary to neutralize or prevent the onset of, or to alleviate, the associated symptoms; and is beneficial.
[0029] Furthermore, the polyribonucleotides used according to the invention may also contain further functional The 3' and / or 5' non-coding regions may include or 5' non-coding regions are sequences that naturally flank the encoded protein, or may be an artificial sequence that contributes to the stabilization and / or regulation of said polyribonucleotide. Suitable sequences can be identified and investigated by routine experimentation. The nucleotides may also have further functional domains, e.g., those encoding proteins. The activity of a desired polyribonucleotide containing a sequence can be determined, for example, in a particular cell or cell type and To control spatially and temporally, and / or with respect to developmental stages or specific time frames. , can be combined with regulatory elements and target sequences of microRNAs.
[0030] The polyribonucleotides used according to the invention are derived from the natural sequences used. The codon optimization may include a partial or complete codon-optimized sequence. In some cases, there are codons that are preferentially used by some species for a given amino acid. By increasing the translation efficiency of each polyribonucleotide, It also refers to a technique applied to maximize protein expression. The compound may include further modifications to modulate and / or extend the duration of action. The polyribonucleotide also contains an m7GpppG cap, an internal ribosome entry site, (IRES), and / or a polyA tail at the 3' end, and / or to promote translation It may contain further sequences for
[0031] In some embodiments of the present invention, the polyribonucleic acid used in accordance with the present invention A nucleotide may contain unmodified and modified nucleotides. As used herein, the term "nucleotide" refers to A, C, G and U nucleotides. "Modified nucleotides" refer to any naturally occurring or naturally occurring nucleotide of A, C, G, and U. non-naturally occurring isomers, as well as any naturally occurring or naturally occurring analogues; For example, alternative or modified nucleotides or isomers thereof having chemically modified or substituted residues. Modified nucleotides can have a base modification and / or a sugar modification. Nucleotides may also be used to modify phosphate groups, for example, for the 5-prime cap of an mRNA molecule. Modified nucleotides can have a covalent modification of the nucleotide. It also includes nucleotides synthesized post-transcriptionally. In addition, unmodified nucleotides and Any suitable mixture of modified nucleotides is possible. Examples of numbers can be found in the literature (e.g., Cantara et al., Nucleic Acid s Res, 2011, 39(Issue suppl_1):D195-D201 ; Helm and Alfonzo, Chem Biol, 2014, 21( 2):174-185; Carell et al., Angew Chem In t Ed Engl, 2012, 51(29):7110-31). Some preferred modified nucleotides are based on their respective nucleoside residues. The following are mentioned by way of example: 1-Methyladenosine, 2-Methylthio-N6-hydroxynorvalylcarbamoyladenosine Adenosine, 2-methyladenosine, 2'-O-ribosylphosphate adenosine, N6-methyladenosine N6-threonylcarbamoyl adenosine, N6-acetyl adenosine, N6-glutamyl Lysinylcarbamoyl adenosine, N6-Isopentenyladenosine, N6-Methyladenosine, N6-Threonylcarbamo Iladenosine, N6,N6-Dimethyladenosine, N6-(cis-hydroxyisopentenyl)adenosine Adenosine, N6-hydroxynorvalylcarbamoyl adenosine, 1,2'-O-dimethyladenosine Adenosine, N6,2'-O-dimethyladenosine, 2'-O-methyladenosine, N6,N 6,2'-O-Trimethyladenosine, 2-Methylthio-N6-(cis-hydroxyiso Pentenyl)adenosine, 2-methylthio-N6-methyladenosine, 2-Methylthio-N6-isopentenyladenosine, 2-Methylthio-N6-threonyl Carbamoyl adenosine, N6-2-methylthio-N6-threonylcarbamoyl adenosine cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, 7-methylthio Chiradenosine, 2-methylthio-adenosine, 2-methoxy-adenosine, 2'-amino No-2'-deoxyadenosine, 2'-azido-2'-deoxyadenosine, 2'-fulve 2'-deoxyadenosine, 2-aminopurine, 2,6-diaminopurine, 7-deoxy Aza-adenosine, 7-deaza-8-aza-adenosine, 7-deaza-2-aminopurine , 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7 -Deaza-8-aza-2,6-diaminopurine; 2-Thiocytidine, 3-Methylcytidine , N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-Methylcytidine, 5-hydroxymethylcytidine, 5-hydroxycytidine, Lysidine N4-acetyl-2'-O-methylcytidine, 5-formyl-2'-O-methylcytidine 5,2'-O-dimethylcytidine, 2-O-methylcytidine, N4,2'-O-di Methylcytidine, N4,N4,2'-O-trimethylcytidine, isocytidine, Pseudocytidine, pseudoisocytidine, 2-thio-cytidine, 2'-methyl-2'- Deoxycytidine, 2'-amino-2'-deoxycytidine, 2'-fluoro-2'-deoxycytidine Oxycytidine, 5-iodocytidine, 5-bromocytidine, 2'-Azido-2'-deoxycytidine, 2'-Amino-2'-deoxycytidine, 2' -fluoro-2'-deoxycytidine, 5-aza-cytidine, 3-methyl-cytidine, 1 -methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-l-methyl 4-Thio-l-methyl-1-deaza-pseudoisocytidine 1-methyl-l-deaza-pseudoisocytidine, 2-methoxy-cytidine, 2-methyl 4-Methoxy-5-methyl-cytidine, 4-Methoxy-pseudoisocytidine, 4-Methoxy- l-Methyl-pseudoisocytidine, Zebularine, 5-Aza-Zebularine, 5-Methyl- Zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine; 1-methylguanidine Guanosine, N2,7-dimethylguanosine, N2-methylguanosine, 2'-O-ribosyl Phosphate Guanosine, 7-Methylguanosine, Hydroxyguanosine, 7-Amino Methyl-7-deazaguanosine, 7-cyano-7-deazaguanosine, N2,N2-dimethyl Trimethylguanosine, N2,7,2'-O-trimethylguanosine, N2,2'-O-dimethyl Guanosine, 1,2'-O-dimethylguanosine, 2'-O-methylguanosine, N2 ,N2,2'-O-trimethylguanosine, N2,N2J-trimethylguanosine, isoguanosine, 4-demethylguanosine, epo Kisikuewooshin, Undermodified hydroxywhibutosine, methylated unmodified hydroxywhibutosine Kisiwibutosin, Isowyosin, Peroxywyosin, Galactosyl-Queuosin, Mannosyl- Que Wo Xin, Queuosine, Archeuosine, Wybutosine, Methylwyocine, Wyocine, 7-Amin Nocarboxypropyl demethylwyosine, 7-aminocarboxypropyl wyosine, 7-Aminocarboxypropyl guanosine methyl ester, 7-deaza-guanosine, 7 -Deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6- Thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1- Methylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1 -Methyl-6-thio-guanosine, N2-Methyl-6-thio-guanosine, N2,N2- Dimethyl-6-thio-guanosine, N1-methylguanosine, 2'-amino-3'-deoxyguanosine 2'-azido-2'-deoxyguanosine, 2'-fluoro-2'-deoxyguanosine Oxyguanosine, 2-thiouridine, 3-(3-amino-3-carboxypropyl)uridine Lysine, 3-methyluridine, 4-thiouridine, 5-methyl-2-thiouridine, 5- Methylaminomethyluridine, 5-carboxymethyluridine, 5-carboxymethylaminomethyluridine Aminomethyluridine, 5-hydroxyuridine, 5-methyluridine, 5-taurinomethyluridine Uridine, 5-carbamoylmethyluridine, 5-(carboxyhydroxymethyl)uridine Lysine methyl ester, dihydrouridine, 5-methyldihydrouridine, 5-methyla Aminomethyl-2-thiouridine, 5-(carboxyhydroxymethyl)uridine, 5-( carboxyhydroxymethyl)-2'-O-methyluridine methyl ester, 5-(iso Pentenylaminomethyl)uridine, 5-(isopentenylaminomethyl)-2-thiouridine Lysine, 3,2'-O-dimethyluridine, 5-carboxymethylaminomethyl-2'- O-Methyluridine, 5-carbamoylhydroxymethyluridine, 5-carbamoylmethyl 5-carbamoylmethyl-2'-O-methyluridine, 5-carbamoylmethyl-2-thiouridine, 2'-O-methyluridine, 5-(isopentenylaminomethyl) 2'-O-methyluridine, 5,2'-O-dimethyluridine, 2'-O-methyl Uridine, 2'-O-methyl-2-thiolidine, 2-thio-2'-O-methyluridine Uridine 5-oxyacetic acid, 5-methoxycarbonylmethyluridine, Uridine 5-oxyacetic acid methyl ester, 5-methoxyuridine, 5-aminomethyl-2 -Thiouridine, 5-Carboxymethylaminomethyl-2-thiouridine, 5-Methylaminomethyl-2- Selenouridine, 5-methoxycarbonylmethyl-2-thiouridine, 5-taurinomethy uridine, pseudouridine, 1-Methyl-3-(3-amino-3-carboxypropyl)pseudouridine, 1-Methyl Lepseudouridine, 3-methylpseudouridine, 2'-O-methylpseudouridine , 5-formyluridine, 5-aminomethyl-2-geranyluridine, 5-taurinomethyl Uridine, 5-iodouridine, 5-bromouridine, 2'-methyl-2'-deoxyuridine Uridine, 2'-amino-2'-deoxyuridine, 2'-azido-2'-deoxyuridine uridine, 2'-fluoro-2'-deoxyuridine, inosine, 1-methylinosine, 1, 2'-O-Dimethylinosine, 2'-O-Methylinosine, 5-Aza-uridine, 2-Thio O-5-aza-uridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-Carboxymethyl-uridine, 1-Carboxymethyl-pseudouridine, 5-Pro 1-Propynyl-pseudouridine, 1-Taurinomethyl-pseudouridine Uridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio- Uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-l-methyl l-pseudouridine, 2-thio-l-methyl-pseudouridine, 1-methyl-l-de Aza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihy Doropseuduridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine uridine, 2-methoxyuridine, 2-methoxy-4-thiouridine, 4-methoxy-sh Pseudouridine, 4-methoxy-2-thio-pseudouridine, 1,2'-O-dimethyl Denosine, 1,2'-O-dimethylguanosine, 1,2'-O-dimethylinosine, 2, 8-Dimethyladenosine, 2-Methylthiomethylenethio-N6-isopentenyl-adenosine Synthin, 2-geranylthiouridine, 2-lysidine, 2-methylthio cyclic N6-threonyl Carbamoyl adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) Adenosine, 2-Methylthio-N6-hydroxynorvalylcarbamoyl adenosine, 2 -methylthio-N6-threonylcarbamoyl adenosine, 2-Selenouridine, 2-thio-2'-O-methyluridine, 2'-O-methyladenosine 2'-O-methylcytidine, 2'-O-methylguanosine, 2'-O-methylinosine uridine, 2'-O-methylpseudouridine, 2'-O-methyluridine, 2'-O-methyl Uridine 5-oxyacetic acid methyl ester, 2'-O-ribosyladenosine phosphate, 2'- O-ribosylguanosine phosphate, 3,2'-O-dimethyluridine, 3-(3-amino-3-carboxypropyl)-5,6-dihydrouridine, 3-(3- Amino-3-carboxypropyl)pseudouridine, 5,2'-O-dimethylcytidine , 5,2'-O-dimethyluridine, 5-(carboxyhydroxymethyl)-2'-O- Methyluridine methyl ester, 55-(isopentenylaminomethyl)-2'-O-methyl Thiouridine, 5-aminomethyl-2-geranylthiouridine, 5-aminomethyl-2- Selenouridine, 5-aminomethyluridine, 5-carbamoylmethyl-2'-O-methyluridine Uridine, 5-carboxyhydroxymethyluridine, 5-carboxymethyl-2-thiouridine Auridine, 5-carboxymethylaminomethyl-2-geranylthiouridine, 5-cal 5-Carboxymethylaminomethyl-2-selenouridine 2'-O-methyluridine, 5-cyanomethyluridine, 5-formyl-2'-O-methyl 5-Methoxycarbonylmethyl-2'-O-methyluridine, 5-methylamino Aminomethyl-2-geranylthiouridine, 7-aminocarboxypropyl-demethylw Guanosine, 7-methylguanosine, 8-methyladenosine, N2,2'-O-dimethylguanosine Guanosine, N2,7,2'-O-trimethylguanosine, N2,7-dimethylguanosine, N2,N2,2'-O-trimethylguanosine, N2,N2,7-trimethylguanosine , N2,N2,7-trimethylguanosine, N4,2'-O-dimethylcytidine, N4, N4,2'-O-trimethylcytidine, N4,N4-dimethylcytidine, N4-acetyl -2'-O-methylcytidine, N6,2'-O-dimethyladenosine, N6,N6,2'-O-trimethyladenosine, N6-formyl adenosine, N6-hydro oxymethyladenosine, Agmatidine, 2-methylthio cyclic N6-threonylcarbamoyl adenosine, glutamine Luke Osin, Guanosine added to any nucleotide, guanylated 5' end, hydroxy-N6- Threonylcarbamoyl adenosine; most preferably, pseudouridine, N1-methyl -pseudouridine, 2'-fluoro-2'-deoxycytidine, 5-iodocytidine, 5-Methylcytidine, 2-thiouridine, 5-iodouridine and / or 5-methyl -Uridine.
[0032] Additionally, the term "modified nucleotide" refers to a nucleotide that contains an isotope, such as deuterium. The term "isotopes" refers to atoms that have the same number of protons but different numbers of neutrons and different masses. Thus, for example, isotopes of hydrogen are not limited to deuterium, but include tritium, In addition, polyribonucleotides also contain, for example, carbon, oxygen, nitrogen and Modified nucleotides may contain isotopes of other elements, including deuterated nucleotides and fluorophores. or contain other isotopes of hydrogen or oxygen, carbon, nitrogen or phosphorus It is also possible to do so.
[0033] The total number of modified nucleotide types in a polyribonucleotide can be 0, 1, 2, 3, or 4. Thus, in some embodiments, at least one of one nucleotide type At least one of the nucleotides, e.g., at least one U nucleotide, can be a modified nucleotide. In some embodiments, at least one nucleotide out of a total of two nucleotide types is nucleotide, e.g., at least one U nucleotide and at least one C nucleotide In some embodiments, a total of three nucleotide types may be used. At least one nucleotide, e.g., at least one G nucleotide, At least one U nucleotide and at least one C nucleotide are modified nucleotides. In some embodiments, at least one of all four nucleotide types may be present. In all of these embodiments, one nucleotide may be a modified nucleotide. One or more nucleotides per nucleotide type may be modified, and The percentage of modified nucleotides is 0%, 2.5%, 5%, 7.5%, 10%, and 15%. , 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% , 70%, 75%, 80%, 85%, 90% or 100%.
[0034] In some embodiments, modified nucleotides included in the purified mRNA molecules The total percentage of %, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80 %, 85%, 90% or 100%.
[0035] Therefore, the polyribonucleotide is, for example, 0.5 to 50%, preferably 5 to 50%. of U nucleotides and 5-50% of C nucleotides are modified The modified U nucleotide is preferably 5-iodouridine, and the modified C The nucleotide is preferably 5-iodocytidine.
[0036] In some embodiments, the polyribonucleotide contains 15-25% U nucleotides. and 3 to 15%, preferably 5 to 15%, of C nucleotides are modified. wherein the modified U nucleotide is preferably 5-methyl U The modified C nucleotide is preferably 5-iodocytidine.
[0037] In some embodiments, the polyribonucleotide contains 30-50% U nucleotides. and 10 to 20% of C nucleotides are modified, Wherein, the modified U nucleotide is preferably 5-iodouridine, and the modified The selected C nucleotide is preferably 5-iodocytidine.
[0038] In some embodiments, the polyribonucleotide contains 30-50% U nucleotides. and 5 to 15% of C nucleotides are modified, wherein the modified U nucleotide is preferably 5-iodouridine, The selected C nucleotide is preferably 5-iodocytidine.
[0039] In some embodiments, the polyribonucleotide contains 0.5 to 5% U nucleotides. and 25-35% of C nucleotides are modified, Wherein, the modified U nucleotide is preferably 2-thiouridine, and the modified The selected C nucleotide is preferably 5-methylcytidine.
[0040] The polyribonucleotide may be, for example, 50 to 100%, preferably 100%, U nucleotides. The modified U nucleotide may be preferably Most commonly, it is N1-methyl-pseudouridine.
[0041] As described above, according to the present invention, administration of a pharmaceutical composition to a patient suffering from a ciliopathic disease is carried out so that the subject In the context of the present invention, the term "inflammation" refers to an infection. Respiratory inflammation refers to the cellular response to injury, including respiratory tract inflammation, trauma, and hypersensitivity. system, particularly but not limited to the nose, pharynx, larynx, trachea, bronchi and / or lungs. Inflammatory responses in the respiratory system can occur due to, for example, pathogens, toxins, pollutants, and / or may be caused by irritants such as allergens. During inflammation, e.g. They can release cytokines and mediators to modify the activity of other cells. Certain cell types are activated. These processes include: aki et al. (Iwasaki et al., 2017, Nat Re v Immunol, 17(1):7-20).
[0042] Thus, in one embodiment, a subject suffering from a ciliopathic disease to which polyribonucleotides are administered is The affected subject is then subjected to a series of treatments to determine whether the subject is suffering from respiratory inflammation. The subject has previously been subjected to an assay in which the subject is positively determined to have respiratory inflammation. It has been done.
[0043] Preferably, the inflammation of the respiratory system is acute inflammation. Acute inflammation can last for seconds, minutes, hours, or It can occur over a period of a few days, but not over a longer period. The inflammation is inflammation occurring over a time frame of up to 4 weeks, preferably less than 3 weeks. Localized increased blood flow, localized increased permeability of capillaries, and / or increased proliferation of neutrophils and macrophages. Routine laboratory tests are based on increased numbers of phages and / or lymphocytes. Further studies on markers of airway inflammation in primary ciliary dyskinesia can be performed. Further information is provided, for example, by Zihlif et al. 2006, Pediatr Pulmonol, 41(6):509-14) Odor It can be found.
[0044] In general, inflammation can be classified as either acute or chronic. Acute inflammation is a response to harmful stimuli. The body's response to chronic inflammation is characterized, for example, by increased migration of granulocytes into affected tissues. The classical signs of inflammation are heat, pain, redness, swelling, and loss of function. The disorder is genetic and, if untreated, can result in permanent, lifelong irritation due to loss of function. This causes persistent and chronic inflammation, but typically does not show the above symptoms (functional Further examples of diseases associated with chronic inflammation are e.g. hay fever, periodontal disease, atherosclerosis, and osteoporosis. However, these diseases are mainly caused by osteoarthritis, osteoporosis, and osteoarthritis. Affected patients may further receive additional harmful stimuli, resulting in the development of the classic inflammation One or more of the classic symptoms, such as redness, pain, swelling, and fever, may be present. Such loss of function can lead to acute inflammation.
[0045] Thus, in one embodiment, a subject suffering from a ciliopathic disease to which polyribonucleotides are administered is The affected subject is subjected to a test to determine whether the subject is suffering from acute inflammation of the respiratory system. and if the subject is positively determined to have acute inflammation of the respiratory system, is provided prior to the procedure.
[0046] Alternatively or additionally, inflammation of the respiratory system refers to an exacerbation of inflammation, preferably an acute exacerbation of inflammation. An exacerbation is when a disease worsens or its symptoms get worse. It reduces quality of life, accelerates the decline of lung function, and contributes substantially to disease-related costs. Therefore, it is most often studied in the context of chronic obstructive pulmonary disease (COPD).
[0047] In clinical trials, "respiratory exacerbations were not associated with any clinical symptoms, regardless of bacterial culture results. , respiratory tract symptoms leading to initiation of systemic antibiotic treatment, or antibiotics with or without prescription and 10% predicted FEV1% compared with the mean at screening and randomization Any percentage point or greater predicted decline in forced expiratory volume in 1 second (FEV1) The occurrence of an exacerbation can be defined as either a chronic or chronic disease. At each study visit and at any special contact with the study site due to progression Participants were interviewed about symptoms and concomitant medications since their last contact with the study site. The interviews are supplemented by weekly patient diaries of symptoms and antibiotics. A physical examination to review the participant's general condition, vital signs, ears, heart and lungs. A physical examination can be performed at every visit" (see, for example, Kobber nagel et al., 2016, BMC Pulmonary Medici ne, 16:104).
[0048] Thus, according to a preferred embodiment, the pharmaceutical composition is administered to a subject suffering from a ciliopathic disease. The mRNA comprises an mRNA for use in treating a ciliopathic disease in a subject, the mRNA being characterized in that the deficiency The present invention relates to a method for the preparation of a ciliary disease-related ciliopathies, comprising: Administration of the pharmaceutical composition to the respiratory system of a subject suffering from a ciliary disease is It is performed in cases of acute inflammation of the system, preferably an acute exacerbation.
[0049] Thus, in one embodiment, a subject suffering from a ciliopathic disease to which polyribonucleotides are administered is The subject is then examined to determine whether the subject is suffering from acute inflammation of the respiratory system, preferably an acute exacerbation. The subject is subjected to an assay prior to treatment to determine whether the subject has a positive respiratory tract infection. The patient has been determined to have chronic inflammation of the system, preferably an acute exacerbation.
[0050] The presence or absence of inflammation in the respiratory tract of subjects suffering from ciliopathies can be determined by standard methods, e.g., blood samples. By analyzing the pull, or whether the patient is suffering from running nose etc. By determining, it can be determined.
[0051] In the respiratory system, inflammation is commonly caused by infection, especially viral or bacterial infections. Therefore, the presence or absence of inflammation in patients with ciliopathies is a sign of infection, preferably The presence or absence of acute infection can be assessed. viral and / or bacterial infections.
[0052] Acute infections are diagnosed by auscultation findings, purulent cough, infiltrates, hemoptysis, fever, and blood inflammatory parameters. characterized by elevated serum erythrocyte sedimentation rate (c-reactive protein (CRP) > 200 mg / ml, erythrocyte sedimentation rate < 100 mm / hour) Chronic infections are further characterized by migratory infiltration, antibiotic resistance, persistent systemic symptoms, and moderate to severe infections. The blood inflammatory markers (CRP 50-100mg / ml, ESR <50mm / h) (Clinische Pneumonologie, 1. Auf l. 2014 Georg Thieme Verlag KG, ISBN 978 -3-13-129751-8; Jaroszewski et al., 2012 , Thorac Surg Clin, 22(3):301-24).
[0053] In the context of the present invention, the term "respiratory system" refers to the nose, pharynx, larynx, trachea, bronchi and In particular, the respiratory system is the organ involved in breathing, such as the lining of the mouth and the lungs. In the case of an object, it is also referred to as the respiratory system, and is also referred to herein as the subject. The terms "respiratory system" and "pulmonary system" are used interchangeably. The respiratory tract is divided into the upper and lower respiratory tract. The upper respiratory tract includes the nose, which includes the nasal cavity, nasal conchae, nasal vestibule, and nasal cavity; the paranasal sinuses; the pharynx; The lower airway includes the part of the larynx above the vocal cords. The lower respiratory tract includes the parts of the larynx that are connected to the lungs, the trachea, the bronchi, and the bronchioles. Includes respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli.
[0054] In the context of the present invention, the term "pharmaceutical composition" refers to a pharmaceutical composition administered to a subject to treat a ciliopathic disorder. The term "polyribonucleotide" refers to a composition comprising at least the polyribonucleotide according to the present invention for the purpose of The nucleotides are preferably administered in an effective amount, i.e., in an amount that is detectable in the subject to which the pharmaceutical composition is administered. The pharmaceutical compositions of the present invention are preferably prepared in a sterile aqueous or non-sterile form. The liquid may be in the form of a non-aqueous solution, suspension or emulsion or aerosol. Alternatively, the pharmaceutical composition may be administered, for example, by inhalation, nebulization, spray, or drops (e.g., a nasal spray or is a form that allows for administration to the respiratory system via nasal drops.
[0055] This means that administration using sprays, drops, nebulizers, or inhalation may be tolerated by patients. It is easy to administer, comfortable to deliver and therefore tolerable to the patient without restricting freedom of action. It is an advantage to the patient as it is readily available.
[0056] In a preferred embodiment, the pharmaceutical composition is DNAI1, CCDC40, CCDC103, SPAG1, ZMYND10, ARMC4 , CCDC151, DNAI2, RSPH1, CCDC114, RSPH4A, DNAA Selected from the group consisting of F1(LRRC50), DNAAF2(KTU), and LRRC6 The vector can be delivered in a spray, droplet, or liquid form, containing mRNA that can be translated into a functional version of the protein to be expressed. By using a nebulizer and / or by inhalation, The protein is administered to a subject suffering from PCD caused by a deficiency. The quality is CCDC40 and / or CCDC39.
[0057] Pharmaceutical compositions may be formulated with pharma- ceutically acceptable carriers, i.e., carriers that, within the bounds of sound medical judgment, may be administered in excess of has been used in humans and Chemical compounds suitable for use in contact with animal tissue, with a reasonable benefit / risk ratio The term "pharmaceutical product" refers to a product, material, ingredient, and / or composition that is pharma- ceutically acceptable. Possible carriers should be handled with due consideration to dosage, adsorption, solubility, or pharmacokinetic considerations. It is an inactive substance that is formulated together with a pharma- ceutical active substance to facilitate the Examples of pharma- ceutically acceptable carriers are well known in the art and include phosphate buffered saline solution. , buffer solutions, water, emulsions, such as oil / water emulsions, various types of wetting agents, and sterile solutions. In particular, aqueous carriers include water, alcoholic / aqueous solutions, emulsions, and the like. or suspensions, including saline and buffered media. Pyrene glycol, polyethylene glycol, vegetable oils such as olive oil, and oleic acid Further examples of pharma- ceutically acceptable carriers include organic esters such as ethyl phosphate. , saline, Ringer's and dextrose solutions, citrates, phosphates, and others of organic acids; salt-forming counterions, e.g., sodium and potassium; low molecular weight (>10 amino acids residues) polypeptides; proteins, e.g., serum albumin, or gelatin; hydrophilic polymers , e.g., polyvinylpyrrolidone; amino acids, e.g., histidine, glutamine, lysine, aspartate arginine, arginine, or glycine; glucose, mannose, or dextrin Carbohydrates including monosaccharides, disaccharides, other sugars, e.g., sucrose, mannitol, trehalose, etc. or sorbitol; chelating agents, e.g., EDTA; non-ionic surfactants, e.g., Tween Polyoxyethylene sorbitan monolaurate, commercially available under the trademark propylene glycol, pluronic or polyethylene glycol; methionine, ascorbyl antioxidants, including oleic acid and tocopherol; and / or preservatives, e.g., octyl chloride; Benzalkonium chloride;Cutadecyldimethylbenzylammonium chloride;Hexamethonium chloride Benzethonium chloride; phenol, butyl or benzyl alcohol; alkylpara Ben, e.g., methyl or propylparaben; catechol; resorcinol; cyclohexa 3-pentanol; and m-cresol). Suitable pharma- ceutically acceptable carriers and their formulations are described in Remington's Pharmaceutical Sciences, 17th ed., 1985, Mack Publishing Co., Inc., 1999. agents, stabilizers and other additives, such as antimicrobial agents, antioxidants, chelating agents, and inerts Gases, nanosystems or liposomes etc. may also be present.
[0058] The pharmaceutical compositions of the present invention can be administered by injection into the respiratory tract, for example, using sprays, drops, inhalers, nebulizers, etc. The present invention provides a method for administering the present invention to a patient via a wide variety of dosage forms known to those skilled in the art to be suitable for administration to the patient. The dosage and duration of action may be determined by the amount of said polyribonucleotide administered to the subject. It depends on the function to be fulfilled and must be deliberately adjusted in each case. The duration of use may be, for example, when the polyribonucleotide is, as in the present case, a defective gene. i.e., when used for chronic treatment of diseases caused by altered DNA sequences, The duration may also be adjusted to a predefined time window.
[0059] In one embodiment, the pharmaceutical composition is administered at least once a week. It is advantageous to ensure an efficient and sustained effect of the treatment. Preferably, the pharmaceutical composition comprises At least 2 weeks, more preferably at least 3 weeks, even more preferably at Alternatively, the pharmaceutical composition is administered weekly for at least one week, preferably at least At least 2 weeks, more preferably at least 3 weeks, and even more preferably at least 4 weeks In one embodiment, after an initial four week treatment as described above, further If a treatment consisting of the above is required, the treatment is administered once a week. or for a longer period, for example, at least 2 months, preferably at least 3 months, more preferably Preferably for at least 4 months, even more preferably for at least 5 months, most preferably can be switched to once-monthly dosing for at least 6 months.
[0060] In one preferred embodiment, the pharmaceutical composition is administered to a subject in an appropriate solution, preferably hypertonic saline. After inhaling a mucolytic agent such as a solution of saline or N-acetylcysteine (NAC) or a suitable solution, preferably Or hypertonic saline or mucolytic agents such as N-acetylcysteine (NAC), After irrigating the nasal passages and / or paranasal sinuses with an appropriate solution, preferably a mucolytic agent, The pharmaceutical composition is then administered to the respiratory system of the elephant by the subject in an appropriate solution, preferably Inhalation of mucolytic agents such as a solution of hypertonic saline or N-acetylcysteine (NAC) Preferably, the compound is administered to the subject's respiratory system after coughing, which is located on epithelial cells. Therefore, polyribonucleoside is used to expose epithelial cells prior to administration of the pharmaceutical composition. This is particularly advantageous for enhancing the transfection efficiency of peptides.
[0061] Thus, in one embodiment, a patient suffering from a ciliopathic disease to which polyribonucleotides are administered is Prior to treatment, subjects should be administered an appropriate solution, preferably hypertonic saline or N-acetylcysteine. By inhaling a mucolytic agent such as a solution of (NAC) or their nasal and / or Alternatively, the sinuses can be filled with an appropriate solution, preferably hypertonic saline or N-acetylcysteine (NAC ) and subjects exposed to the agent by washing with a mucolytic agent.
[0062] Such a process may involve physically removing mucus from the subject's respiratory system prior to administration of the polyribonucleotide. The purpose is to remove
[0063] Further, such a subject is preferably a subject suffering from inflammation of the respiratory system, preferably acute inflammation or The control group was assayed before treatment to determine whether they suffered from exacerbation of inflammation. The subject is a patient suffering from inflammation of the respiratory system, preferably acute inflammation or exacerbation of inflammation. It has been positively decided.
[0064] In a preferred embodiment, the concentration of NAC in the solution is 3% to 20%, preferably 5% to 15%, more preferably 8% to 12%, most preferably 10%. The ratio is weight / weight. Preferably, the solution containing NAC also contains sodium edetate ( EDTA refers to ethylenediaminetetraacetate) and / or sodium hydroxide The solution preferably contains a medicament in a pharma- ceutically acceptable concentration.
[0065] Several embodiments of pharmaceutical compositions containing polyribonucleotides for use in the treatment of ciliopathies are described. In an embodiment, the pharmaceutical composition comprises a mucolytic agent, such as N-acetylcysteine (NAC), and and / or a hypertonic solution containing sodium chloride. Both hypertonic solutions containing sodium chloride reduced the formation of viscous mucus in subjects with PCD. This is advantageous for reducing the risk of respiratory infections and therefore This can reduce additional stress for the patient.
[0066] In a preferred embodiment, the pharmaceutical composition further comprises NAC in the concentrations as described above.
[0067] In a preferred embodiment, the pharmaceutical composition is present in an amount of 2% to 8%, preferably 3% to 7%, more preferably The solution further contains a hypertonic solution containing sodium chloride at a concentration of 4% to 7%.
[0068] In a preferred embodiment, the pharmaceutical composition contains NAC at 3% to 20%, preferably 5% to 15%. , more preferably 8% to 12%, most preferably 10%, and / or sodium chloride at a concentration of 2% to 8%, preferably 3% to 7%, more preferably 4% to 7%. Further includes:
[0069] As described above, in a preferred embodiment of the pharmaceutical composition according to the invention, said pharmaceutical composition are DNAH5, DNAH11, CCDC39, DNAI1, CCDC40, and CCDC1. 03, SPAG1, ZMYND10, ARMC4, CCDC151, DNAI2, RSP H1, CCDC114, RSPH4A, DNAAF1(LRRC50), DNAAF2( KTU), and LRRC6, preferably from CCDC40 and / or CCDC39 The present invention includes an mRNA that can be translated into a functional version of a protein selected from the group consisting of: Such a pharmaceutical composition is hereinafter also referred to as the "first pharmaceutical composition".
[0070] Multiciliate differentiation and DNA synthesis associated cell cycle (MCIDAS) proteins are involved in the regulation of multiciliate differentiation and DNA synthesis. This transcriptional regulatory protein is specifically required for insect cell differentiation, and is involved in the differentiation of multiple ciliate cells. Multidrug-resistant ciliate formation (e.g., human mRNA and protein MCIDs) The AS sequences are referenced in NCBI reference sequences NM_001190787.1 and N P_001177716.1; or the optimized polyribonucleotide sequence shown in SEQ ID NO:4 (See ).
[0071] Thus, the present invention provides a pharmaceutical composition comprising a polyribonucleotide for use in the treatment of ciliopathies. In some embodiments, the pharmaceutical composition comprises a multiciliate differe ntiation and DNA synthesis associated ce Polyribonucleic acid (PRI) encoding functional versions of the ll cycle (MCIDAS) proteins It further comprises nucleotides.
[0072] In some embodiments, the pharmaceutical composition comprises a polypeptide encoding an MCIDAS protein. The first pharmaceutical composition described above, administered together with a second pharmaceutical composition comprising a ribonucleotide. It is an object.
[0073] Both pharmaceutical compositions, i.e., polyribonucleic acid encoding the MCIDAS protein, The first pharmaceutical composition further comprising a tide encoding an MCIDAS protein. The first pharmaceutical composition administered together with the second pharmaceutical composition comprising a polyribonucleotide comprises: The pharmaceutical composition according to the invention is administered to cells prior to and / or during ciliary formation. Advantageously, it is particularly effective in restoring ciliary cell structure and function when used in combination with other agents. , both preferably by using a nasal spray and / or nebulizer. and / or by inhalation, preferably at least once a week and / or at least is also administered to the patient for four weeks.
[0074] In some embodiments, the pharmaceutical composition contains two or more functional versions of a protein. This includes, for example, a polyribonucleotide that can be translated into two or more different transcripts. Polycistronic polyribonucleoside, a single polyribonucleotide that codes for a protein For example, such polycistronic sequences can be constructed using the 2A peptide. Designing polyribonucleotides is well documented in the literature. demonstrated the use of 2A peptide to generate multicistronic mRNAs (Li et al. u et al., 2017, Scientific Reports, 7:21 93) These 2A peptides have also been shown to mediate ribosomal skipping ( Additional amino acids ( It can be combined with a furin cleavage site to remove the 2A peptide (part of the 2A peptide). As an example, the use of furin cleavage with the 2A peptide is described, for example, by Chng et al. (Chng et al., 2015 MAbs, 7(2):403-412) Thus, two or more, preferably two, therapeutic proteins (e.g. A single polyribonucleotide encoding the ribosomal RNA (CCDC40, CCDC40 and MCIDAS) was designed. wherein the coding regions for the two therapeutic proteins are (See Fig. 2A) and are separated by the 2A peptide.
[0075] Thus, in some embodiments, the pharmaceutical composition comprises two or more, preferably two, tanks. The above, except that the nucleic acid sequence includes a polyribonucleotide that can be translated into a functional version of a protein. The same applies as described for the previous embodiment. In an embodiment, the pharmaceutical composition according to the above embodiment is 39, DNAI1, CCDC40, CCDC103, SPAG1, ZMYND10, AR MC4, CCDC151, DNAI2, RSPH1, CCDC114, RSPH4A, D NAAF1 (LRRC50), DNAAF2 (KTU), and LRRC6, preferably Functionality of a protein selected from the group consisting of CCDC40 and / or CCDC39 A sequence that can be translated into a functional version of the MCIDAS protein, It includes polycistronic polyribonucleotides that contain sequences that can be translated.
[0076] In some embodiments, the pharmaceutical composition translates into a functional version of the MCIDAS protein. and a polyribonucleotide sequence comprising the optimized polyribonucleotide sequence shown in SEQ ID NO:4. and translating it into functional versions of the CCDC40 and / or CCDC39 proteins. and SEQ ID NO: 1 (or SEQ ID NO: 5 to 11) and / or SEQ ID NO: 2 (or SEQ ID NO: Polyribonucleotides containing the optimized polyribonucleotide sequences shown in numbers 12 to 14) Preferably, it is administered by using a nasal spray and / or a nebulizer. and / or by inhalation, preferably at least once a week and / or It will be administered to the patient for at least four weeks.
[0077] Instead of or in addition to MCIDAS, e.g., GemC1, FoxJ1, and and / or E2f4VP16. GemC1 is specific for ciliated epithelia. GemC1 is expressed in the nucleus and is a central regulator of ciliogenesis. Ectopic expression of GemC1 inhibits the 2-phase multiciliary formation. Upregulating two key transcriptional regulators, MCIDAS and FoxJ1 This induces the early stages of multiciliary formation in airway epithelial cells ex vivo. It has been reported that this is sufficient to EMBO reports, 17(3):400-413). Furthermore, in the same study Thus, GemC1 can directly transactivate MCIDAS and FoxJ1 upstream regulatory sequences. It has been reported that E2f4VP16 is a general activation domain from HSV1 VP16. domain and positively affect the activation of expression of key genes related to hirsutogenesis (Kim S et al., Scientific Reports, Reports, 2018, 8:12369).
[0078] Thus, the present invention provides a pharmaceutical composition comprising a polyribonucleotide for use in the treatment of ciliopathies. In some embodiments, the pharmaceutical composition is the first pharmaceutical composition described above, Polyribonucleotide encoding a functional version of the S protein, function of the GemC1 protein a polyribonucleotide encoding a functional version of the FoxJ1 protein; ribonucleotides, and / or polypeptides encoding a functional version of the E2f4VP16 protein The nucleic acid further comprises at least one of the following ribonucleotides:
[0079] In some embodiments of the pharmaceutical composition, the first pharmaceutical composition contains the following functional groups: and administering the composition together with a second pharmaceutical composition comprising at least one of the polyribonucleotides administered A polyribonucleic acid sequence encoding a functional version of the MCIDAS protein can be provided. A polyribonucleotide encoding a functional version of the GemC1 protein, FoxJ1 protein A polyribonucleotide encoding a functional version of the protein, and / or an E2f4VP16 tag. Compact quality.
[0080] Both pharmaceutical compositions, i.e., MCIDAS, GemC1, FoxJ1, and / or The above-mentioned method further comprises the step of: 1, or MCIDAS, GemC1, FoxJ1, and / or E2f together with a second pharmaceutical composition comprising a polyribonucleotide encoding the 4VP16 protein. The first pharmaceutical composition administered to the cells before or during ciliary formation When administered directly to cells, administration of a pharmaceutical composition according to the present invention restores ciliary cell structure and function. Advantageously, both are particularly effective in treating chronic conditions such as nasal sprays and and / or by using a nebulizer and / or by inhalation, The therapeutic agent is administered to the patient at least once a week and / or for at least four weeks.
[0081] As noted above, in some embodiments, the pharmaceutical composition comprises two or more, preferably two except that it contains a polyribonucleotide that can be translated into a functional version of one protein. The same applies to the above embodiment. In some embodiments, the pharmaceutical composition described in the above embodiments contains multicistronic It contains a polyribonucleotide.
[0082] Pharmaceutical compositions facilitate transfection of cells with polyribonucleotides Examples of such compounds are described in WO 2014 / 20723. It is disclosed.
[0083] The pharmaceutical composition is a pharmaceutical composition for delivering and / or introducing RNA into a target cell or tissue. It may further comprise one or more drugs or one or more reagents. In particular, this / these The agent or reagent supports the delivery and / or introduction of RNA into a cell or tissue. This / these agents or reagents may be administered together with the RNA. The introduced RNA may also be coupled (e.g., covalently coupled) to this / these agents (or reagents). The nucleotides may be coupled (e.g., bound or complexed) or uncoupled (e.g., simply (It may be mixed with this / these drugs (or reagents) at the same time. Drugs are known in the art (see, e.g., Tavernier, J Control Rel. ease 150(3)(2011),238-47), and, for example, lipids, among others. and selected from the group consisting of liposomes, micelles, polymers and dendrimers. Specific examples of each drug or agent include GL67, EDMPC, DOTAP (l,2- Dioleyl-3-trimethylammonium propane, DODAP (1,2-dioleyl -3-dimethylammonium propane), DOTMA (l,2-di-0-octadecenyl -3-trimethylammoniumpropane), XTC (2,2-dilinoleyl-4-dimethyl arylaminoethyl-[1,3]-dioxolane) and MC3 (((6Z,9Z,28Z, 31Z)-Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(di methylamino)butanoate), ALNY-100 ((3aR,5s,6aS)-N,N -Dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetra Hydro-3aH-cyclopenta[d][1,3]dioxol-5-amine), NC9 8-5(4,7,13-tris(3-oxo-3-(undecylamino)propyl)-N l,N16-Diundecyl-4,7,10,13-tetraazahexadecane-l,16- diamide), C12-200, DLin-KC2-DMA, DODAP, l,2-distearate Allyloxy-N,N-dimethyl-3-aminopropane or "DSDMA", l,2- Dioleyloxy-N,N-dimethyl-3-aminopropane or "DODMA", 2-Dilinoleyloxy-N,N-dimethyl-3-aminopropane or "DLinDM A”, 1,2-diaminolinoloxy-N,N-dimethyl-3-aminopropane or “D LenDMA," N-Dioleyl-N,N-Dimethylammonium Chloride or "DO DAC", N,N-distearyl-N,N-dimethylammonium bromide or "DD AB", N-(l,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N -Hydroxyethylammonium bromide or "DMRIE", 3-Dimethylamino- 2-(cholest-5-en-3-beta-oxybutan-4-oxy)-l-(cis, cis-9,12-octadecadienoxy)propane or "CLinDMA", 2-[ 5'-(cholest-5-en-3-beta-oxy)-3'-oxapentoxy)-3- Dimethyl ll-(cis,cis-9',1-2'-octadecadienoxy)propane or "CpLinDMA", N,N-dimethyl-3,4-dioleyloxybenzyl aryl amine or "DMOBA", l,2-N,N'-dioleylcarbamyl-3-dimethylamine Diaminopropane or "DOcarbDAP", 2,3-dilinoleoyloxy-N,N- Dimethylpropylamine or "DLinDAP", l,2-N,N'-dilinoleylamine Incarbamyl-3-dimethylaminopropane or "DLincarbDAP", l,2-di Linoleoylcarbamyl-3-dimethylaminopropane or "DLinCDAP", 2 ,2-Dilinoleyl-4-dimethylaminomethyl-[l,3]-dioxolane or "D Lin-K-DMA", 2,2-dilinoleyl-4-dimethylaminoethyl-[l,3] -dioxolane or "DLin-K-XTC2-DMA", or a mixture thereof (Heyes, J Controlled Release 107 (2005) , 276-287; Morrissey, Nat. Biotechnol. 2 3(8) (2005), 1003-1007;WO 2005 / 121348 A further example is DC-Chol (N,N-dimethyl-N-ethylcarboxamide Chole sterol), l,4-bis(3-N-oleylamino-propyl)piperazine ( Gao, Biochem. Biophys. Res. Comm. 179 (1 991), 280; Wolf, et al BioTechniques 23 (1997), 139; U.S. Patent No. 5,744,335). Further examples include LIP OFECTIN(DOTMA:DOPE)(Invitrogen, Carlsbad , Calif), LIPOFECTAMINE(DOSPA:DOPE)(Invit rogen), LIPOFECTAMINE2000.(Invitrogen), FU GENE, TRANSFECTAM (DOGS), and EFFECTENE. Further examples include modified and unmodified polyacrylates, polyalkoxysilanoacrylates, poly Lactide, polylactide-polyglycolide copolymer, polycaprolactone, dextran , albumin, gelatin, alginate, collagen, chitosan, cyclodextrin , polylysin, polyarginine, oligo / polyamines and poly It is ethyleneimine.
[0084] The drugs or agents may be oligomeric, polymeric or lipidoids. For example, the characteristic oligo(alkylene) derivatives described in PCT / EP2014 / 063756 In particular, the compound may contain an oligo(alkyleneamine) moiety, such as an oligo(alkyleneamine) moiety. The reagents may be oligomers, polymers, or the like, as described in PCT / EP2014 / 063756. One main feature of these particular drugs or agents is that they , that they contain a common structural entity of formula (I): [ka]
[0085] Such agents or reagents are oligo(alkyleneamines) selected from the group consisting of: Optional: a) an oligomer or polymer comprising a plurality of groups of formula (II) as side chains and / or end groups; MA: [ka] where the variables a, b, p, m, n and R 2 ~R 6 The formula (II) among multiple such groups Each group of is independently defined as follows: a is 1 and b is an integer from 2 to 4; or a is an integer from 2 to 4 and b is 1 and p is 1 or 2; m is 1 or 2; n is 0 or 1 and m+n is ≧2; and R 2 ~R 5are, independently of each other, hydrogen; the group -CH-CH(OH)-R 7 , -CH(R 7 )-CH2-OH, -CH2-CH2-(C=O)-OR 7 , -CH2-CH2-(C =O)-NH-R 7 or -CH2-R 7 wherein R 7 is one CC C3-C18 alkyl or C3-C18 alkenyl with double bonds; amino group protecting group and a poly(ethylene glycol) chain; R 6 is hydrogen, the group -CH-CH(OH)-R 7 , -CH(R 7 )-CH2-OH, -C H2-CH2-(C=O)-OR 7 , -CH2-CH2-(C=O)-NH-R 7 Also -CH2-R 7 wherein R 7 is a C3-C with one C-C double bond 18 alkyl or C3-C18 alkenyl; amino group protecting group; -C(NH)-NH2 a poly(ethylene glycol) chain, and a receptor ligand; and wherein one or more of the nitrogen atoms represented by formula (II) are protonated to form the formula (II) may provide a cationic group; b) an oligomer or polymer comprising multiple groups of formula (III) as repeat units : [ka] where the variables a, b, p, m, n and R 2 ~R 5 The formula (II) among multiple such groups Each group in I) is independently defined as follows: a is 1 and b is an integer from 2 to 4; or a is an integer from 2 to 4 and b is 1 and p is 1 or 2; m is 1 or 2; n is 0 or 1 and m+n is ≧2; and R 2 ~R 5 are, independently of each other, hydrogen; the group -CH-CH(OH)-R 7 , -CH(R 7 )-CH2-OH, -CH2-CH2-(C=O)-OR 7 or -CH2-CH2- (C=O)-NH-R 7 or -CH2-R 7 wherein R 7 is one C- C3-C18 alkyl or C3-C18 alkenyl with a double bond; a protecting group; -C(NH)-NH2; and a poly(ethylene glycol) chain; In addition, one or more of the nitrogen atoms represented by formula (III) are protonated to form a compound represented by formula (II I) cationic groups; and c) A lipidoid having the structure of formula (IV): [ka] where the variables a, b, p, m, n and R 1 ~R 6 is defined as follows: a is 1 and b is an integer from 2 to 4; or a is an integer from 2 to 4 and b is 1 and p is 1 or 2; m is 1 or 2; n is 0 or 1 and m+n is ≧2; and R 1 ~R 6 are, independently of each other, hydrogen; the group -CH-CH(OH)-R 7 , -CH(R 7 )-CH2-OH, -CH2-CH2-(C=O)-OR 7 , -CH2-CH2-(C =O)-NH-R 7 or -CH2-R 7 wherein R 7 is one CC C3-C18 alkyl or C3-C18 alkenyl with double bonds; amino group protecting group -C(NH)-NH2; a polyethylene glycol chain; and a receptor ligand; R 1 ~R 6 At least two of the residues are the groups -CH-CH(OH)-R 7 , -CH( R 7 )-CH2-OH, -CH2-CH2-(C=O)-OR 7 , -CH2-CH2- (C=O)-NH-R 7 or -CH2-R 7 where R 7 One CC duplex selected from C3-C18 alkyl or C3-C18 alkenyl having a bond; and wherein one or more of the nitrogen atoms represented by formula (IV) are protonated to form a compound represented by formula (IV) may be provided.
[0086] Preferably, such a drug or agent is an oligo(amino)mer selected from a) and b). alkyleneamine) (component containing the same), a) an oligomer or polymer containing a plurality of groups of formula (IIa) as side chains and / or terminal groups Rimmer: -NR 2 {CH2-(CH2) a -NR 3 -CH2-(CH2) b -NR 4} m -[ CH2-(CH2) a -NR 5 ]n -R 6 (IIa), In the formula, a, b, m, n, and R 2 ~R 6 is defined as above and shown in formula (IIa) One or more of the nitrogen atoms in the aryl group may be protonated to form a cationic oligomeric or polymeric structure. and b) an oligomer or polymer containing multiple groups of formula (IIIa) as repeating units; Is: -NR 2 {CH2-(CH2) a -NR 3 -CH2-(CH2) b -NR 4} m -[ CH2-(CH2) a -NR 5 ] n - (IIIa), In the formula, a, b, m, n, and R 2 ~R 5 is defined as above and shown in formula (IIIa) One or more of the nitrogen atoms that are bonded to the aryl group may be protonated to form a cationic oligomeric or polymeric structure. The present invention may provide a structure.
[0087] Further, such a drug or agent may be prepared from a lipidoid having the structure of formula (IVa): The component may comprise a selected oligo(alkyleneamine): R 1 -NR 2 {CH2-(CH2) a -NR 3 -CH2-(CH2) b -NR 4} m -[CH2-(CH2) a -NR 5 ] n -R 6 (IVa), In the formula, a, b, m, n, and R 6 R to1 is defined as above and shown in formula (IVa) One or more of the nitrogen atoms may be protonated to provide a cationic lipidoid.
[0088] With regard to such agents or reagents, the formula (II), (IIa), (III), (III In (IVa), (IV) or (IVa), n may be 1; or m is 1. and n may be 1.
[0089] Further, such drugs or reagents include those represented by formula (II), (IIa), (III) In (IIIa), (IV) or (IVa), a is 1 and b is 2. or a may be 2 and b may be 1.
[0090] In some embodiments, the oligomer, polymer, or lipidoid is cationic (e.g. , protonated) oligomers, polymers, or lipidoids.
[0091] A non-limiting example of such an oligomer, polymer or lipidoid that may be used is 10 0 mg of N,N'-bis(2-aminoethyl)-1,3-propanediamine (0.623 mmol) to 575.07 mg of 1,2-epoxydodecane (3.12 mmol) (N- 1) equivalents (where N is 2x the amount of primary amine and 1x the amount of secondary amine / oligo(alkoxy) The mixture was prepared by mixing with 1,2-diphenylamine (1,2-diphenylamine) and mixing at 80°C under constant shaking for 96 hours. Such oligomers, polymers or lipidoids are cationic lipids. Ido is also called "C12-(2-3-2)".
[0092] The agent or reagent used, in particular the polymer, is a copolymer, in particular a statistical copolymer. Such copolymers may include (e.g., alkylene amine repeating units of non-alternating length). Alternating length polymers (as opposed to the less preferred polymers that contain similar arrangements of units) It may be a copolymer containing a statistical / random arrangement of xyleneamine repeat units. The copolymer may be a cationic (e.g., protonated) copolymer. Such copolymers are known in the art and are described, for example, in EP 14 19 9439.2, WO 01 / 00708, EP-A1 1 198 489 and CA-A1 2 ,377,207.
[0093] In particular, the copolymer comprises repeat units independently selected from the repeat units of the following formulae (a1) and (a2): The copolymer may be a statistical copolymer comprising a plurality of repeat units (a) selected from: [ka] , and A plurality of repeating units independently selected from the repeating units represented by the following formulae (b1) to (b4): b): [ka] In the formula, the molar ratio of the total number of repeating units (a) to the total number of repeating units (b) is 0.7 / Within the range of 1.0 to 1.0 / 0.7, and In the formula, one of the nitrogen atoms of the repeating units (a) and / or (b) contained in the copolymer One or more may be protonated to provide a cationic copolymer.
[0094] A copolymer is a copolymer in which any repeating unit (a) and any repeating unit (b) are copolymers. It may also be a statistical copolymer, which is statistically distributed in the polymer. During the polymerization reaction, repeating units (a) are produced with the monomer, and during the polymerization reaction, The copolymer is obtained by copolymerization of a mixture of monomers which give rise to the unit (b). Any repeating unit (a) and any repeating unit (b) are randomly arranged in the polymer. It is a random copolymer with a distribution of
[0095] Such copolymers may be linear, branched or dendritic copolymers. As will be appreciated, the repeating units of formula (a1), (b1) or (b3) have two valences. (i.e., open bonds to adjacent units) and also allows propagation of the copolymer structure in a linear fashion. Thus, a linear copolymer contains repeat units of formula (a1) as well as repeat units of formula (b1) and (b3), but may contain one or more types of repeat units of formula (a2), (b2) or does not include the repeat unit (b4). As will be further understood, The presence of repeat units of formula (a2), (b2) or (b4) provides branching in the copolymer structure. Thus, the branched copolymer is a repeat of the formulas (a2), (b2) and (b4). The repeating units are of one or more types of formula (a1), (b1) and (b3). It may further include one or more types of repeating units.
[0096] Such copolymers may comprise repeating units of formulae (a1) and (a2) as defined above. and a plurality of repeating units (a) independently selected from the formulas (b1) to (b2) defined above. and b4) a plurality of repeating units (b) independently selected from the repeating units (b) and Preference is given to repeating units of the formulae (a1) and (a2) defined above. A plurality of independently selected repeating units (a) and a compound represented by the formula (b1) and (b2) as defined above. and a plurality of repeating units (b) independently selected from the repeating units (b2). It's Ma.
[0097] Preferably, such copolymers comprise repeating units (a2), (b2) and (b4) and optionally comprising one or more types of repeat units selected from the formula (a1), (b1 ) and (b3), in particular comprising one or more types of repeat units of the formula (a2) repeat units and one or more types of repeat units of formula (b2) and (b4), Optionally, one or more types of repeat units of formula (a1), (b1) and (b3) may be further In line with the above, therefore, a more preferred copolymer is of the formula ( a2) and repeating units of formula (b2), optionally comprising repeating units of formula (a1) and and (b1) is a branched copolymer further comprising one or more types of repeat units of do.
[0098] In a copolymer, the total number of repeat units (a) and repeat units (b) is typically The repeat number is 20 or more, preferably 50 or more, and more preferably 100 or more. The total number of repeat units (a) and repeat units (b) is 10,000 or less, preferably 5, 000 or less, more preferably 1,000 or less.
[0099] Furthermore, the repeating units (a) and (b) are 8 of all repeating units in the copolymer. It is preferred for the copolymer to have a molar ratio of 0.05 or more, more preferably 90.05 or more. More preferably, the repeating unit (a) is selected from (a1) and (a2). and (b1) and (b2) are selected from the repeating units (b) in the copolymer. At least 80 mol %, more preferably at least 90 mol %, of all repeating units are account copies. All of the repeating units in the copolymer are either repeating units (a) or (b). It is most preferred that all of the repeating units in the copolymer are (a1) and (a 2) or a repeating unit selected from (b1) and (b2) Repeating units (b) are most preferred.
[0100] The weight average molecular weight of the copolymers is, for example, a linear poly(ethylene oxide) standard. When measured by size exclusion chromatography, the average is generally 1,000 to 500,000. 00 Da, preferably 2,500 to 250,000 Da, more preferably 5,000 to 5 The range is less than 0,000 Da.
[0101] The end groups of such copolymers are typically selected from the group of the following formulae (c1) to (c3), preferably Preferably, one or more types independently selected from the group of the following formulas (c1) and (c2): containing the group (c) of: [ka] .
[0102] Preferably, the end groups in the copolymer are selected from the group of the following formulae (c1) to (c3), preferably is selected from one or more types of groups (c) independently selected from the group of formulas (c1) and (c2): As will be appreciated by those skilled in the art, the number of end groups will depend on the structure of the copolymer. Copolymers have only two ends, whereas more numerous end groups result in branched, especially dendritic, copolymers. As will be further understood, the nitrogen atom of the terminal group (c) contained in the copolymer One or more of may also be protonated to provide a cationic copolymer.
[0103] In the copolymer, the molar ratio of the sum of the repeating units (a) to the sum of the repeating units (b) is The ratio is in the range of 0.7 / 1.0 to 1.0 / 0.7, preferably 0.8 / 1.0 to 1. 0 / 0.8. This molar ratio can be determined, for example, by NMR. Therefore, this ratio is usually determined for multiple polymers of a copolymer, typically The overall ratio of the sum of repeat units (a) to the sum of repeat units (b) in multiple polymers It will be understood that this indicates the following.
[0104] As shown above, one or more of the nitrogen atoms of the copolymer can be protonated to form a cationic form. This results in copolymers in the form, typically oligocationic or polycationic form. The primary, secondary repeating units (a) or (b) or the terminal groups (c) may be Primary and tertiary amino groups are particularly prone to proton transfer in water and aqueous solutions (including physiological fluids). It is understood that the copolymer may act as a receptor. Generally, the aqueous solution has an overall positive charge below pH 7.5. The solution should contain at least 50% (vol. / vol.) solvent, preferably at least 80 or 90%. Most preferably, the solution contains 100% water. Also, the composition may be used in the preparation of, for example, blood and lung fluid. When in contact with physiological fluids that have a pH below 7.5, including The composition contains repeat units (a) and (b) in which the nitrogen atoms are protonated. The pK of the copolymer used ina The value is auto pK a Acid-base titration using a titrator The net charge at a given pH value can then be determined using, for example, He It can be calculated from the Derson-Hasselbach equation. It may be shared across several basic centers and not necessarily ascribed to a single point. Typically, in a solution at physiological pH, the components used in the composition The polymers consist of repeating units with protonated amino groups and repeating units with protonated amino groups. It includes repeating units having an amino group in an unoccupied state.
[0105] However, as will be appreciated by those skilled in the art, the copolymers as well as the compositions may also include It may be provided as a dry salt form that contains the copolymer in cationic form.
[0106] As will be further understood, the copolymer and nucleic acid, particularly RNA, preferably mRNA, etc. A counterion ( The positively charged anion is typically provided by an anionic moiety contained in the nucleic acid. If the charged groups are present in excess compared to the anionic moieties in the nucleic acid, the positive charge will be transferred to other anions. On, especially Cl - or HCO3 - Animals typically encountered in physiological fluids such as It can be balanced by on.
[0107] In accordance with the above, preferred copolymers are random copolymers. 80 mol % or more of all repeating units, more preferably all repeating units, are Formed A plurality of repeating units independently selected from repeating units of the following formulae (a1) and (a2): Place (a): [ka] , and A plurality of repeating units independently selected from repeating units of the following formulae (b1) and (b2): Place (b): [ka] , In the formula, the molar ratio of the sum of repeating units (a) to the sum of repeating units (b) is 0.7 / 1. It is in the range of 0 to 1.0 / 0.7, and more preferably 0.8 / 1.0 to 1.0 / 0.8. is in range; wherein the end groups of the copolymer are formed by A group (c) independently selected from the groups of formulae (c1) and (c2): [ka] ; and In the formula, the repeating units (a) and / or (b) and / or terminal repeating units (a) and / or terminal repeating units (b ... One or more of the nitrogen atoms of the end group (c) are protonated to provide a cationic copolymer. The copolymer may also contain units (a2) and (b2), and optionally units (a1) and It is further preferred that the copolymer comprises (b1) and / or (b2).
[0108] The copolymers may be polyalkylenes, such as branched or linear polyethyleneimines (PEIs). The copolymers can be conveniently prepared by procedures similar to those known for the preparation of copolymer imines. It is understood that the monomers used in the preparation of the polymer must be adjusted accordingly. It is understood that the monomer ratio in the monomer mixture to be polymerized is appropriately adjusted. In order to adjust the ratio of units (a) and (b) in the copolymer, We found that it is possible to quantitatively react the monomers with ease. For example, the copolymer can be prepared by ring-opening polymerization of aziridine, Azetidine, and where applicable pyrrolidine, or in a preferred embodiment aziridin by ring-opening polymerization of a monomer mixture containing or consisting of azetidine and azetidine The phrase "where applicable" refers to the compound formed by pyrrolidine. It is understood that this refers to the presence or absence of repeat units (b3) and (b4) or terminal group (c3). Ring-opening polymerization of unsubstituted cyclic amines usually leads to branched copolymers. Such copolymers are described, for example, in Katrien F. Weyts, Eric J. Goe thals, New synthesis of linear polyethyl eneimine, Polymer Bulletin, 1988, 19(1): Analogous to the procedures published in [13-19], for example, the appropriate N-substituted aziridines, N-substituted Aziridine and N-substituted pyrrolidine, or N-substituted aziridine and N-substituted aziridine can be prepared by polymerization of an alkylene group, followed by, for example, polymerization of the resulting polyalkylene group. Hydrolytic cleavage of the N-substituents attached to the imine chains can be carried out. Dendrimers are e.g. For example, Yemul et al, Colloid and Polymer Sci. nce, 2008, 286(6-7):747-752, Synthesis a nd characterization of poly(ethylenimine) ) It can be synthesized according to the method described in Denrimers.
[0109] For the preparation of dendrimers (or dendritic copolymers), polyethyleneimine or The synthetic strategies known for the preparation of polypropyleneamine dendrimers can be similarly applied. Polypropylenimine dendrimers can be used to react with primary amines in the Michael addition reaction. Using the repeat sequence, it can be synthesized from acrylonitrile building blocks, which can then be used in heterogeneous catalysis. can be synthesized using catalytic hydrogenation (Newkome and Shreiner Poly(amidoamine), polypropylenimine, and related dendrimers and dendrons possess ing different 1→2 branching motifs: An o verview of the divergent procedures. ymer 49 (2008) 1-173; De Brabander-Van D en Berg et al. Large-scale production of polypropylenimine dendrimers, Macromole ocular Symposia (1994) 77 (1) 51-62). The lenimine dendrimers are based on the vinyl bromide building blocks attached to primary amines. Addition of the alkyl bromide to an amine is then performed using the Gabriel amine synthesis method. The repeat sequence of Michael addition can be used to prepare the ae, Synthesis and characterization of po ly(ethyleneimine) dendrimers, Colloid Po Lym Sci (2008) 286:747-752). Therefore, those skilled in the art For example, dendrimers with strictly alternating layers of propyleneimine and ethyleneimine can be prepared. Similarly, the compounds represented by formula (a2), (b2) and and (b4), and preferably the repeating units (a2) and (b2) Creating dendrimer generations having layers that include or consist of random compositions It is possible.
[0110] Ring opening of aziridine and azetidine, or aziridine, azetidine and pyrrolidine The polymerization can be carried out in a solution, for example in water. The total monomer concentration is not particularly limited. Typical concentrations are 10% wt / wt to 80% wt / wt, preferably 30% wt / wt. t~60% wt / wt. Typically, polymerization is initiated by protons. Therefore, it is preferable to add a Bronsted acid, particularly a mineral acid such as sulfuric acid, to the reaction system. A small amount of acid, such as 0.001 to 0.01 equivalents based on the total concentration of the monomer, is generally sufficient. The reaction proceeds at a convenient rate, for example at temperatures in the range of 50 to 150°C, particularly 90 to 140°C. Within these ranges, higher molecular weight copolymers typically require higher temperatures and better At lower temperatures it is a lower molecular weight copolymer.
[0111] In principle, lipidoids are particularly preferred over oligomers and more particularly polymers. are preferred agents or reagents used for
[0112] One or more agents for delivering and / or introducing the RNA into a target cell or tissue. Further examples of the one or more reagents include liposomes as described elsewhere herein. The main transfection reagents are long-range transfection reagents (LTR's) and magnetic particles (MP).
[0113] 1. Delivery and / or introduction of RNA into target cells or tissues One particular mode is transfection. Thus, the RNA used is ( To transfect a target cell or tissue; via transfection To be delivered / administered and / or prepared for transfection It is envisioned that means and methods for transfecting RNA are well known in the art. For example, see Tavernier (ibid.) and Yamamoto (Eur JP harm Biopharm. 71(3)(2009), 484-9) and Korma nn (Nat Biotechnol. 29(2)(2011), 154-7) Specific modes of transfection include lipofection, magnetofection, or magnetopolypofection.
[0114] Thus, the RNA used may be prepared for lipofection and It can be prepared to be transfected by lipofection and delivered by lipofection. The antibody may be delivered / introduced into the host and / or administered by lipofection.
[0115] Thus, the pharmaceutical composition may (further) comprise at least one lipid or liposomal trans Transfection reagent or enhancer (LTR; liposomal transfection reagent The RNA used may be contained in the LTR, complexed with the LTR, and In particular, the RNA used may be delivered by RNA and / or LTR. Incorporated and / or delivered by the (respective) lipofection complex containing the LTR The pharmaceutical composition may (further) comprise a lipofection complex.
[0116] LTRs are known in the art and are available, for example, from OzBiosciences, Marseille The LTRs used are those that target RNA to cells. The group consisting of the above-mentioned agents or reagents for delivery and / or introduction into cells or target tissues. For example, such LTRs can be selected from the LTRs described in PCT / EP2014 / 063756 ( For example, lipidoids such as those disclosed in C12-(2-3-2) and EP 2285772 (e.g., Dogtor) and lipids as disclosed in EP 1003711 (e.g., , DreamFect (trademark) and DreamFect Gold (trademark) Lipids or lipidoids, preferably cationic lipids, such as lipopolyamines, or a cationic lipid. The particular LTR may be selected from the group consisting of (i) C12-(2-3-2); (ii) DreamFect™, preferably DreamFect Gold™ )(DF(TM) / DF-Gold(TM); OzBiosciences, Marse ille, France); (iii) Dogtor (OzBiosciences, Marseille, Fr. ance); and (iv) For example, Lipofectamine 2000 (Invitrogene, CA, Lipofectamine such as USA.
[0117] In principle, Dogger is preferred, DreamFect™ is more preferred, and DF-Gold™ and C12-(2-3-2) are more preferred LTRs.
[0118] Dogtor-like LTRs are described, for example, in EP2285772. For example, LTRs such as DF™ and DF-Gold™ are described in EP1003711. In principle, the application as disclosed in PCT / EP2014 / 063756 Ligomers, polymers or lipids, specific cationic Preferred are cyclic lipids, and certain lipopolyamines, such as those disclosed in EP 1003711. LTRs such as C12-(2-3-2) and DF-Gold (trademark) are preferred. It has the highest priority.
[0119] A non-limiting example of a lipofection complex is the DF-Gold™ / RNA lipofection complex. and C12-(2-3-2) / RNA lipoplexes.
[0120] C12-(2-3-2) is a particularly preferred LTR having the structure shown in formula (V) (Jarzebinska et al., Angew Chem Int Ed Engl., 20 16; 55(33):9591-5): [ka]
[0121] C12-(2-3-2) is preferably, for example, Nflett, EP 3013964, and Jarzebinska et al. (Angew C hem Int Ed Engl., 2016;55(33):9591-5) The cationic lipid is N1-(2-aminoethyl)-N3-(2-( (3,4-Dimethoxybenzyl)amino)ethyl)propane-1,3-diamine (8.9 g, 1 equiv., 28.67 mmol) to 1,2-epoxydodecane (42.27, 8 equiv., 229.4 mmol) and mixed at 80°C under constant shaking for 24 hours, followed by purification. , can be prepared by removal of the 3,4-dimethoxybenzyl protecting group.
[0122] Different C12-(2-3-2) isomers, such as racemic, S-isomer, and / or R-isomer Preferably, C12-(2-3-2) is a pure R-isomer. It is used as a dimer and has the structure shown in formula (VI). To obtain the pure R-isomer, the R-isomer of 1,2-epoxydodecane was synthesized. can be prepared as described above for C12-(2-3-2). [ka]
[0123] Thus, in a preferred embodiment, the pharmaceutical composition is for use in the treatment of a ciliopathic disease. and is represented by formula (V), preferably by formula (VI): The lipidoids further include lipidoids having a structure such as:
[0124] A further particularly preferred LTR is a cationic lipidoid having the formula (VII), Also referred to as "dL_P" in the specification, this is the synthesis of N,N'-bis(N-phenylalanine) using boric acid as a catalyst. Bis(2-aminoethyl)-1,3-propanediamine and N-dodecylacrylamide For the reaction, the mixture is heated at 10 Can be stirred at 0°C.
[0125] Thus, in a further preferred embodiment, the pharmaceutical composition is for use in the treatment of ciliopathies. The structure represented by formula (VII) further comprises a lipidoid. has. [ka]
[0126] Additionally, pharmaceutical compositions include those comprising the compounds of formula (V), (VI) and / or (VII) in the formulations described below. or (VII), preferably dL_P and / or C12-(2-3-2), more preferably or cationic with R-isomer of dL_P and / or C12-(2-3-2) In particular, the RNA described herein can be delivered to and / or delivered to a target cell or tissue. Agents and reagents for the introduction or transfer of the LTRs described herein include one or more For example, two, three, or four additional lipids (e.g., cholesterol, DPPC, D OPE and / or PEG lipids (e.g., DMPE-PEG, DMG-PEG2000 These additional lipids can be combined with the drug / reagent and the LTR. The desired function can be supported (by delivering and / or introducing RNA into a cell or tissue, respectively). (which may support and / or increase and improve transfection efficiency), and Each of these can function as a "helper lipid"; specific examples of such "helper lipids" include are cholesterol, DPPC, DOPE and / or PEG lipids (e.g., DMPE- PEG, DMG-PEG (e.g., DMG-PEG2000). For example, "helper lipids") can also be part of the complexes / particles disclosed herein. A person skilled in the art is readily in a position to prepare complexes / particles according to the invention. Examples of lipids (e.g., "helper lipids") are also known in the art. and a lipid (e.g., a "helper lipid") and a drug / agent / LTR and a further lipid. (e.g., "helper lipids") in such a molar ratio of 1- 4:1-5, 3-4:4-6, approx. 4:approx. 5, approx. 4:approx. 5:drugs / reagents / LTR Approximately 5.3: and lipid(s) (narrower ranges are preferred). For example, drugs / reagents / LTR is 8 : 5.3 : 4.4 : 0.9 respectively, or more specifically The molar ratio of DPPC, cholesterol, and DMSO was 8:5.29:4.41:0.88, respectively. It can be combined with three additional lipids, such as glycerol, glycerol, and DMG-PEG2000. Cut.
[0127] Preferably, dL_P and / or C12-(2-3-2), more preferably dL_ The P and / or R-isomers of C12-(2-3-2) are produced as above, and lipoic acid isomers are To formulate the doped particles, the helper lipids DPPC and cholesterol as well as PEG- The lipid was used in a molar ratio of 8:5.29:4.41:0.88 with DMG-PEG2000. can be.
[0128] The R-isomer of C12-(2-3-2) (Formula VI) is the lipid DPPC and cholesterol and PEG-lipid DMG-PEG2000 with a molar ratio of 8:5.29:4.41:0.88. The composition formulated in the ratio is also referred to herein as "LF92". dL_P (Formula VII) 8 with lipids DPPC and cholesterol and PEG-lipid DMG-PEG2000: The composition formulated in the molar ratio of 5.29:4.41:0.88 is referred to herein as "LF111 " is also called.
[0129] Also, for example, International Publication No. 2016 / 075154 A1, EP 3013964, and Zhang et al. (TERMIS, 2019, Tissue En gineering: Part A, Vol. 25, Numbers 1 an d 2) As exemplified in dL_P and / or C12-(2-3-2) is due to electrostatic interactions between the positive amino groups of lipidoids and the negative phosphate groups of mRNA molecules. Based on the above, a non-viral vector for generating stable lipoplexes with mRNA molecules (Anderson, Human Gene Therapy, 14, 2003, 191-202). It stabilizes the lipoplex structure and reduces leakage. In order to achieve this, dL_P and / or C12-(2-3-2), more preferably dL_P and / or C12-(2-3-2) R-isomer with 1,2-dipalmitoyl-sn -glycero-3-phosphocholine (DPPC) and cholesterol (Anderson, Drug Delivery 11, 2004, 33-39; Liang, J ournal of Colliod and Interface Science 278, 2004, 53-62) can supply two helper lipids. Finally, 1,2-dimyristoyl-sn-glycerol, methoxypolyethyleneglycol Choline (DMG-PEG) 2kD (DMG-PEG2000) was added to the lipid mixture, Provides PEGylated liposomes. PEGylation increases water solubility, protects against enzymatic degradation, and enhances immunity. Improve the physicochemical properties of liposomal formulations by limiting immunogenic and antigenic responses. It is already well known that the drug improves Bolism 13, 2012, 105-119). The final total ethanolic lipid mixture The N / P ratio is the ratio of dL_P and / or C12-( 2-3-2) / DPPC / cholesterol / DMG-PEG2000 amino group moiety The ratios of the fluorine-containing compounds are 8:5.29:4.41:0.88, respectively.
[0130] Thus, in a preferred embodiment, the pharmaceutical composition comprises a polyclonal antibody for use in the treatment of a ciliopathic disease. It contains ribonucleotides, DPPC, cholesterol, and DMG-PEG2000. Prescribed dL_P and / or C12-(2-3-2), preferably dL_P and and / or further includes the R-isomer of C12-(2-3-2).
[0131] Furthermore, in a particularly preferred embodiment, the pharmaceutical composition is for use in the treatment of ciliary lipids. Further comprising polyribonucleotides, preferably dL_P and / or C12-(2- 3-2), preferably containing dL_P and / or C12-(2-3-2) R-isomers It was formulated with DPPC, cholesterol, and DMG-PEG2000 and was dL_P and / or C12-(2-3-2) / for one phosphate group of the NA molecule The molar ratio of amino groups in DPPC / cholesterol / DMG-PEG2000 was They have final N / P ratios of 8:5.29:4.41:0.88, respectively.
[0132] Formulated with DPPC, cholesterol, and DMG-PEG2000 as above The C12-(2-3-2) R-isomer is also called the LF92 blend.
[0133] Thus, the present invention provides a pharmaceutical composition comprising a polyribonucleotide for use in the treatment of ciliopathies. In a particularly preferred embodiment, the pharmaceutical composition further comprises an LF92 formulation.
[0134] Formulated with DPPC, cholesterol, and DMG-PEG2000 as above The resulting dL_P is also called LF111 formulation.
[0135] Thus, the present invention provides a pharmaceutical composition comprising a polyribonucleotide for use in the treatment of ciliopathies. In a particularly preferred embodiment, the pharmaceutical composition further comprises an LF111 formulation.
[0136] Preferred embodiments of pharmaceutical compositions containing polyribonucleotides for use in the treatment of ciliary diseases In some embodiments, the pharmaceutical composition further comprises a LF92 and / or LF111 combination. LF92 and / or LF111 are carriers used for cell transfection. This refers to the use of LF92 and / or LF111 in high transfection Functional verification of proteins with defects related to ciliopathy and therefore related to transcription efficiency The polyribonucleotide encoding the polypeptide is then administered to a cell, preferably an undifferentiated hair cell or basal cell. Efficiently enters hair follicles, thus restoring hair cell function in subjects suffering from PCD. This is advantageous because it ensures that
[0137] In a particularly preferred embodiment, the pharmaceutical composition comprises the LF92 and / or LF111 sequence. If the MCIDAS protein is a functional version of the MCIDAS protein, the MCIDAS protein may contain at least one of the following: A mRNA that can be translated into a functional version of the GemC1 protein. A, E2f4VP1, an mRNA that can be translated into a functional version of the FoxJ1 protein. 6 mRNA that can be translated into functional versions of the protein; and CCDC40 and and / or an mRNA that can be translated into a functional version of CCDC39. Such compositions may be administered by spray, droplets and / or by using a nebulizer. and / or by inhalation, preferably at least once a week and / or at least It will be administered to patients for four weeks.
[0138] Thus, in some embodiments, the pharmaceutical composition comprises two or more, preferably two, tanks. The above, except that the nucleic acid sequence includes a polyribonucleotide that can be translated into a functional version of a protein. The same applies as described for the previous embodiment. In an embodiment, the pharmaceutical composition described in the above embodiment comprises a multicistronic polynucleotide. Contains ribonucleotides.
[0139] The present invention also relates to a method of treating a ciliopathic disease in a subject suffering from a ciliopathic disease, comprising administering to said subject a polyclonal antibody. The method further comprises administering a pharmaceutical composition comprising ribonucleotides to the patient, the deficiency of which is prevented by administration of polyribonucleotides. The pharmaceutical composition further comprises a polypeptide encoding a functional version of the protein associated with ciliopathies. The pharmaceutical composition is administered to the respiratory system of a subject and is administered when the subject exhibits inflammation of the respiratory system. Possible and preferred embodiments of the present invention, as well as methods and times of administration thereof, The same applies as described herein above in connection with the pharmaceutical composition according to the invention. will be done.
[0140] The present invention also relates to a polyribonucleotide encoding a protein whose deficiency is associated with a ciliopathic disease. , and a hypertonic solution containing N-acetylcysteine (NAC), sodium chloride, and and / or a pharmaceutical composition comprising a LF92 and / or LF111 combination.
[0141] Regarding the pharmaceutical composition and its components, the present invention relates to the treatment of ciliopathies in subjects suffering from ciliopathies. The same as described above in connection with pharmaceutical compositions containing polyribonucleotides for use in the treatment of Moreover, other characteristics of such pharmaceutical compositions may be as described above. .
[0142] Thus, in a preferred embodiment, the pharmaceutical composition is a functional version of MCIDAS. It may further comprise an mRNA that can be translated.
[0143] The present disclosure also relates to a method for producing a human CCDC40 polypeptide comprising the steps of: The present invention relates to a polyribonucleotide that encodes a nucleic acid sequence.
[0144] In some embodiments of any of the above or other aspects and embodiments of the present disclosure, Polyribonucleotides or modified polyribonucleotides are selected from the group consisting of human CCDC40 (e.g., and encoding a functional human CCDC40, and one or more of SEQ ID NOs: 1 or 5 to 11 (e.g., SEQ ID NOs: Sequences shown in columns 1 or 5 to 11) and at least 85%, at least 90%, 92% or at least 95% identical (e.g., at least 95, 96, 97, 98 , 99 or 100% identical).
[0145] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. part of the ter, Ethris' minimal 5' untranslated region (UTR), CYBA 5'UTR , followed by a codon-optimized sequence encoding a functional version of the human CCDC40 protein. The Kozak element, the CYBA 3'UTR, and the poly(A) tail (e.g., sequence See number 1). In a particular embodiment, the polyribonucleotide comprises at its 5' end a T7 promoter A part of the Ethris 'minimal 5' untranslated region (UTR), human CCDC40 protein A Kozak element followed by a codon-optimized sequence encoding a functional version of the protein, and a poly(A) tail (see, e.g., SEQ ID NO:5).
[0146] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. Part of the nucleotide sequence, Ethris' minimal 5' untranslated region (UTR), and additional U nucleotides This is followed by a codon-optimized sequence encoding a functional version of the human CCDC40 protein. It comprises a TISU element, and a poly(A) tail (see, e.g., SEQ ID NO:6).
[0147] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. part of the tRNA, Ethris' minimal 5' untranslated region (UTR), hAg 5'UTR, K followed by a codon-optimized sequence encoding a functional version of the human CCDC40 protein ozak element, and a poly(A) tail (see, e.g., SEQ ID NO:7).
[0148] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. Part of the ter, Ethris' minimal 5' untranslated region (UTR), human CMV IE9 5'UTR, codon-optimized to encode a functional version of the human CCDC40 protein sequence, human growth hormone 3' UTR, and poly(A) tail (see, e.g., SEQ ID NO:8). (including references).
[0149] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. part of the tRNA, Ethris' minimal 5' untranslated region (UTR), and Kozak element , EGFP coding sequence, G4S spacer, followed by the functional domain of human CCDC40 protein. A codon-optimized sequence encoding the version, and a poly(A) tail (e.g., SEQ ID NO: 9).
[0150] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. part of the tRNA, Ethris' minimal 5' untranslated region (UTR), human CCDC40 protein A codon-optimized sequence encoding a functional version of the protein, a G4S spacer, and EGFP coding sequence, and a poly(A) tail (see, e.g., SEQ ID NO:10).
[0151] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. part of the ter, Ethris' minimal 5' untranslated region (UTR), CYBA 5'UTR , Kozak element, followed by HA tag, G4S spacer, and human CCDC40 protein A codon-optimized sequence encoding a functional version of the protein, the T2A peptide, tdToma The sequence encoding the CYBA 3′ UTR and the poly(A) tail (e.g., the sequence (see number 11). In some embodiments, the polyribonucleotide is any such nucleic acid sequence described herein. and / or types of modification selected from the group consisting of: It is a decorated polyribonucleotide.
[0152] In certain embodiments, the percent identity of a polyribonucleotide is SEQ ID NO: 1 or is measured only for the portion of the CCDC40 coding sequence from 5 to 11 (e.g., percent When calculating identity, UTRs, other non-coding sequences and GFP or epitope tags are (The term "polyribonucleotide" does not include any particular region, and the polyribonucleotide may or may not include such regions).
[0153] In certain embodiments of any of the above, such a polyribonucleotide (or The modified polyribonucleotide encodes a functional CCDC40 protein.
[0154] The present disclosure also relates to a human CCDC39 as set forth in any one of SEQ ID NOs: 2 or 12 to 14. It relates to a polyribonucleotide encoding
[0155] In some embodiments of any of the above or other aspects and embodiments of the present disclosure, the polyribonucleotide or modified polyribonucleotide encodes human CCDC39; One or more of SEQ ID NO: 2 or 12 to 14 (for example, sequence) and at least 85%, at least 90%, at least 92%, or at least 95 % identical (e.g., at least 95, 96, 97, 98, 99, or 100% identical) Includes the primary sequence.
[0156] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. Part of the 5′UTR, Ethris' minimal 5′UTR, CYBA 5′UTR, human CCDC 39 Kozak elements followed by codon-optimized sequences encoding functional versions of the proteins ment, CYBA 3'UTR, and poly(A) tail (see, e.g., SEQ ID NO:2) Includes.
[0157] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. A part of the 5'UTR of Ethris and the functional role of the human CCDC39 protein A Kozak element followed by a codon-optimized sequence encoding version 1, and poly(A ) tail (see, e.g., SEQ ID NO:12).
[0158] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. Part of the ter, Ethris' minimal 5'UTR, additional U nucleotides, human CCD The TISU sequence was followed by a codon-optimized sequence encoding a functional version of the C39 protein. ment, and a poly(A) tail (see, e.g., SEQ ID NO:13).
[0159] In a particular embodiment, the polyribonucleotide comprises a T7 promoter at its 5' end. Part of the target, Ethris' minimal 5'UTR, SP30 as the 5'UTR (i.e. A random sequence of 30 nucleotides, followed by a Kozak element and the human CCDC39 protein. A codon-optimized sequence encoding a functional version of the protein, and a poly(A) tail (e.g. See, for example, SEQ ID NO: 14.
[0160] In some embodiments, the polyribonucleotide is any such polyribonucleotide described herein. having a level and / or type of modification selected from the levels and / or types It is a modified polyribonucleotide.
[0161] In certain embodiments, the percent identity of the polyribonucleotide is SEQ ID NO: 2 or 1. Only the CCDC39 coding sequence portion 2-14 is measured (e.g., percent identity). When calculating identity, UTRs, other non-coding sequences and GFP or epitope tags are not considered. (The term "polyribonucleotide" does not include any particular region, and the polyribonucleotide may or may not contain such regions.)
[0162] In certain embodiments of any of the above, such a polyribonucleotide (or The modified polyribonucleotide encodes a functional CCDC39 protein.
[0163] The present disclosure also provides a polyribonucleic acid sequence encoding the human MCIDAS shown in SEQ ID NO:4. Some implementations of any of the above or other aspects and embodiments of the present disclosure. In the form, polyribonucleotides or modified polyribonucleotides bind human MCIDAS. and encoding at least 85% of the sequence shown in SEQ ID NO:4 (e.g., to the sequence shown in SEQ ID NO:4). %, at least 90%, at least 92% or at least 95% identical (e.g., at least 95, 96, 97, 98, 99 or 100% identical to any other sequence. In an embodiment, the polyribonucleotide comprises at its 5' end a portion of a T7 promoter, Ethris' minimal 5'UTR, a functional version of the human MCIDAS protein Codon-optimized sequences encoding reverse primer binding for PCR-based template preparation The 3'UTR also serves as a transcription site, as well as any 3'UTR poly(A) tail. In embodiments, the polyribonucleotides are at any such levels and / or concentrations described herein. or a type of modification selected from the group consisting of: In certain embodiments, the percent identity of a polyribonucleotide is is measured only with respect to the MCIDAS coding sequence portion of SEQ ID NO:4 (e.g., percent When calculating the identity of a gene, the UTR, other non-coding sequences and the GFP or epitope tag are included. (The polyribonucleotide may or may not contain such regions.) In certain embodiments of any of the above, such a polyribonucleotide (or modified polyribonucleotide) encodes a functional MCIDAS protein.
[0164] For purposes of determining the percentage identity of a first sequence to a second sequence, an analyte Log (e.g., methylcytidine) corresponds to cytidine, etc. In certain embodiments, the term The "primary sequence" is the same as CUCUCUA, but is not limited to any of the listed nucleotides. or all of the sequences, whether modified or not (e.g., C Any or more analogs of U and A may be present and considered to be the same primary sequence. ), may be used to refer to a polynucleotide sequence, regardless of the presence or amount of modification. .
[0165] In certain embodiments, the percent identity is, for example, It is determined solely by reference to the portion of a given listed sequence that corresponds to the coding sequence. In other embodiments, the percent identity is determined for a coding sequence and one or more non-coding sequences. In certain embodiments, the percent identity is determined by reference to both the The sequence of interest is determined over the entire length of the sequence listed in the sequence listing of this specification (e.g., by referring to the overall length).
[0166] The present invention further provides a method for analyzing the effect of polyribonucleotides on ciliary formation. Thus, the polyribonucleotide is associated with and / or required for ciliary formation. The method comprises the steps of: (a) obtaining a nose brush from a subject having a ciliopathic disease, the nose brush being an undifferentiated a step of culturing the differentiated basal cells and differentiated ciliated cells; (b) To obtain undifferentiated basal cells and dedifferentiated ciliated cells, the culture medium obtained from step (a) is Cultivating the cells as a submerged cell culture; (c) The undifferentiated basal cells and dedifferentiated ciliated cells obtained from step (b) are cultured at an air-liquid interface. culturing the culture as a cell culture and performing an airlift; (d) subjecting the cells obtained from step (c) to a protein synthesis reaction associated with and / or required for ciliary formation; transfecting the cell with a polyribonucleotide encoding the protein; (e) eluting the transfected cells obtained from step (d) to obtain differentiated ciliated cells; Culturing the cells thus obtained; and (f) The effect of the polyribonucleotide on ciliary formation is examined using lactate dehydrogenase (LDHA). Zeta assay, NucGreen assay, high-speed video microscopy, ciliary beat frequency measurement, mucosa Determining using a ciliary clearance assay and / or immunofluorescence staining.
[0167] To obtain cells from the patient's airway epithelium, a nasal brush is easy to handle and convenient for the patient. The advantage is that it is quick and painless. Cells obtained from nasal brushes are composed of undifferentiated basal cells and Submerged cell cultures contain differentiated ciliated cells that can be cultured as submerged cell cultures. Dedifferentiation of epithelial cells is induced, resulting in undifferentiated basal cells and dedifferentiated ciliated cells. The dedifferentiated ciliated cells and the undifferentiated basal cells of the nasal brush obtained in this manner were then cultured in air-liquid The cells are cultured as interfacial (ALI) cell cultures.
[0168] The air-liquid interface cell culture of step (c) is in contact with the basal surface of the cells in liquid culture medium, while refers to a cell culture characterized in that the apical surface is exposed to air. The cell culture inserts can be initially seeded with apical and basal compartments. Both the basal and confluent compartments are supplied with culture medium. This is also called "air cell culture" and Once at the base of the cell culture, the cells undergo an "airlift" step, where the medium is lifted to the basal chamber. This mimics the conditions found in the respiratory system, for example, and is delivered to undifferentiated ciliary cells. Thus, for example, basal cells and cilia are differentiated into different cellular compartments, including the ciliary body. Cells mimicking respiratory epithelia, including erythrocytes, were obtained for further studies in vitro. It is possible.
[0169] The resulting epithelial mimic cells can then be obtained. Polyribonucleotides are produced Polyribonucleic acid sequences encoding proteins related to and / or required for production Thus, the polyribonucleotide was transfected with the or introduced into cells, which can be done artificially by means other than viral infection, The transfected cells are then transformed with exogenous polyribonucleotides. By culturing, differentiated ciliated cells are obtained from basal and undifferentiated ciliated cells. The effect of polyribonucleotides such as mRNA on somatogenesis can be seen, for example, in subjects. The present invention aims to develop a method for the detection of inflammatory cytokines in vitro, while preserving a cellular environment that mimics the epithelium of the airway system, so that the inflammatory cytokines can be detected in a wide range of tissues. It can be determined.
[0170] The effect of polyribonucleotides on ciliary formation can be determined by a variety of methods known to those skilled in the art. These methods can be determined by, for example, lactate dehydrogenase measurement, NucGreen Assay, high-speed video microscopy, ciliary beat frequency measurement, mucociliary clearance up Therefore, lactate dehydrogenase measurement (L LDH) can be performed to determine the amount of LDH released in the environment surrounding the cells. Each assay can be a colorimetric assay, in which the amount of released LDH is The amount is determined by, for example, converting iodonitrotetrazolium or tetrazolium salts to red formazan. The assay is therefore easily read by spectroscopy. It is possible.
[0171] Alternatively, or in addition, a NucGreen assay can be performed. een is a permanent green fluorescent nucleic acid stain when bound to nucleic acids, e.g., during transfection. Alternatively, or in addition, the present invention can be used to examine the toxicity-related effects of Immunofluorescence of proteins encoded by transfected polyribonucleotides Staining is performed to determine its abundance and cellular localization, including colocalization with other proteins. To determine the amount of expressed protein, Western blot techniques can be used. It is also possible to use Furthermore, defects in the ciliary structures or absence of the ciliary body can be detected, for example, using special microscopic techniques. Screening tests include nasal nitric oxide production rates, high-speed video microscopy of nasal cells, and This includes measuring ciliary motility by microscopy or in vivo tests, including, for example, the saccharin test. A more specific diagnosis may involve, for example, examination of the cilia by immunofluorescence and transmission electron microscopy. is necessary.
[0172] Alternatively or additionally, ciliary beat frequency measurements can be applied using high speed video microscopy. Beating frequency, number of beating cilia and ciliated cells, and beating synchrony can be investigated. The same was done to measure mucus clearance rate as affected by ciliary function. This also applies to mucociliary clearance assays that can be performed.
[0173] Regarding the polyribonucleotides used in the described method, they are useful for treating ciliopathies. The uses of the pharmaceutical compositions of the present invention are similar to those described above. Other features of the polyribonucleotide, such as may also be as described above.
[0174] Additionally, the polyribonucleotide may include a sequence encoding a marker. tdTomato (e.g., contained in SEQ ID NO:3), as described in the accompanying examples; green Fluorescent proteins (GFP) and enhanced GFP (eGFP) and their respective detection methods This method is based on the successful transfection of cells with polyribonucleotides. This is particularly advantageous for verifying the
[0175] Some embodiments of the method for analyzing the effect of polyribonucleotides on ciliary formation In the step (c), the cells are preferably cultured within 0 to 12 days after airlifting in the step (c). or within 0 to 11 days, more preferably within 0 to 6 days, and even more preferably within 0 to 4 days. The transfection is carried out within 0 to 48 hours, most preferably within 0 to 48 hours. This is advantageous because the process induces ciliary formation in basal and undifferentiated ciliary cells.
[0176] Some embodiments of the method for analyzing the effect of polyribonucleotides on ciliary formation In the method, the cell has a structure shown in formula (V), (VI), and / or (VII). Using lipidoids that target proteins related to and / or required for ciliary formation, The polypeptide is transfected with a polyribonucleotide, preferably mRNA, that encodes the polypeptide.
[0177] Some embodiments of the method for analyzing the effect of polyribonucleotides on ciliary formation In the above, the cells are cultured in steps (b) to (e) using medium G. The composition is typically as shown in Table 2.
[0178] [Table 2]
[0179] Some embodiments of the method for analyzing the effect of polyribonucleotides on ciliary formation The cells are cultured in steps (b) to (e) using one of the media shown in Table 3. The media listed in Table 3 can be used to grow ALI cultures. This is a commercially available medium.
[0180] [Table 3]
[0181] Some embodiments of the method for analyzing the effect of polyribonucleotides on ciliary formation In the method, the nasal brush further comprises fibroblasts, and the growth of the fibroblasts is performed by steps (b) to ( e) is inhibited in fibroblasts compared to basal and undifferentiated ciliary body cells. This allows for faster proliferation and therefore the availability of polyribonucleotides for ciliary formation as described above. This is advantageous as it could prevent studies of the effects.
[0182] For a short incubation time of 1-2 hours, cells are incubated for 1-2 hours before transferring to a flask of stationary phase. The fibroblasts can then be separated from the remaining cells. During this time, the fibroblasts settle out. The cells are then allowed to attach to the cell flask. All other cells remain in the medium as suspension cells. , which can then be easily transferred to a "stationary phase flask."
[0183] The method according to the invention preferably has a positive effect on ciliary formation and enhances the function of ciliary cells. To restore cell structure, therefore, the use in the pharmaceutical composition according to the second aspect and the identification of a polyribonucleotide capable of inhibiting ciliopathies according to the first aspect of the present invention. The present invention provides a method for the treatment of ciliopathies in a subject, comprising administering to said subject a polyribonucleic acid or a ribonuclease .... The characteristics of the tide are related to the pharmaceutical composition of the present invention for use in the treatment of ciliopathies. The same applies as stated above for other such polyribonucleotides. The characteristics may also be as described above.
[0184] Figure 1: Translation efficiency of CCDC40 mRNA. 2 / 1.4 / 0.3 / 0.2 / 0.05x 10^6 HEK293 cells were seeded in a 6-well plate. Using e2000, seedling cells were transfected with different CCDC40 constructs (ETH031T06-T 10, 2.5μg / 9.5cm 2 ) for 24 hours. Cell lysis was performed 6, 24, 48, 72, and 144 hours after injection. Protein lysates were analyzed by SDS-PAGE and Western blot. Anti-CCDC40 antibody (HPA022974) from Atlas Antibodies ( 1:2000), and GAPDH served as a loading control. GFP served as a transfection control.
[0185] Figure 2: CCDC in BEAS-2B, RPMI2650, and HEK293 cells. Translation efficiency of 40 mRNA constructs: 2x10^6 HEK293, 7.5x10^5 B EAS-2B and 5x10^5 RPMI 2650 cells were seeded in 6-well plates. 24 hours after seeding, the cells were transfected with Lipofectamine2000. The CCDC40 construct (2.5 μg / 9.5 cm 2 ) was transfected. Cell lysis was performed 6 hours after infection. Protein lysates were analyzed by SDS-PAGE and and Western blot (HEK293: 50 μg, RPMI 2650: 20 μg, B EAS-2B: 30 μg of total lysate) and analyzed with Atlas Antibodies (1: CCDC40 was detected using anti-CCDC40 antibody (HPA022974) from I put it out.
[0186] Figure 3: High-speed video microscopy (HSVM) after LF92 / CCDC40 transfection ) Results. Patient-derived ALI cultures were transfected with 3 μg of LF92 / CCDC40 every other day. Before transfection and 24 hours after transfection. For each video (20 per insert), videos were collected and analyzed using Sisson-Ammo The ciliary beat frequency (CFB) was calculated using the ns video analysis software. The transfection was performed (1 month). The measurement was performed with a magnification of 40 times. The measurements were performed at 37°C using a 100-μm CT scanner. The average ciliary beat frequency measurements were calculated (total magnetic field analysis, WF A).
[0187] Figure 4: Mucociliary clearance (MCC) shown as Z-projection and polar graph. CCDC40 patient ALI cultures were cultured with CCDC40 m The ALI cultures were transfected with RNA / LF92 for 18 days by airlift. During the experiment, the cells were maintained in medium G. Transfection (TF) was performed once a week for 4 weeks. (=4xTF). Mucociliary clearance (MCC) was measured using 0.5 μm fluorescent beads for 2 h. 30 videos of different areas were taken and were then recorded 1 week after the last TF. The images were analyzed with PolarGraph software from Connexion. One exemplary photograph is shown. .
[0188] Figure 5: tdTomato and polar graphs of healthy controls (bottom right), Z-projected ( top left) and mucociliary clearance (MCC) shown as a polar graph (top right). Top: Cells from patients with CCDC40 mutations in ALI cultures were cultured in airlift tubes. After 8 days, the cells were transfected with tdTomato mRNA / LF111 at a concentration of 3 μg / insert. ALI cultures were maintained in medium G for the duration of the experiment. The treatment with TF was performed once a week for 4 weeks (=4xTF). ) was measured at 30x magnification using 0.5 μm fluorescent beads. The images were photographed and analyzed with Polargraph software from Nikon one week after the last TF. One exemplary video was shown. Bottom right: Particle tracking of a healthy WT ALI culture. CC was measured at 20x magnification using 0.5 μm fluorescent beads. The video was taken and analyzed with Nikon's Polargraph software one week after the last TF. One exemplary image and two analyzed ROIs are shown.
[0189] Figure 6: Cells from patients harboring CCDC40 mutations in ALI cultures at the time of air lift tdTomato mRNA / LF111 or CC at a dose of 3 μg / insert for 18 d The ALI cultures were transfected with either DC40 mRNA or LF92. During the experiment, the cells were maintained in medium G. Transfection (TF) was performed once a week for 4 weeks. (=4xTF). As a control, WT ALI from a healthy nose brush was used. CCDC ALI membranes treated with 40 mRNA and tdTomato mRNA were cut at 20 μm. and stained with anti-GAS8 (red), anti-acetylated tubulin (green) and DAPI (blue). Stained and photographed with a confocal microscope. One exemplary image is shown. Scale The bar represents 10 μm.
[0190] Figure 7: Patient-derived cells with CCDC40 mutations in ALI cultures were cultured at 3 µg / insert tdTomato mRNA / LF111 or CCDC40 mRNA / LF 92 and transfected for 18d at the time of airlift. LI cultures were maintained in medium G for the duration of the experiment. Transfections (TF) were performed weekly. , for 4 weeks (=4xTF). ALI from healthy controls was used as a control. CC ALI membranes treated with DC40 mRNA and tdTomato mRNA were sliced at 20 μm. Cleaved and stained with anti-DNALI1 (red), anti-acetylated tubulin (green) and DAPI ( The cells were stained with 500 mM NaCl (blue). Photographs were taken with a confocal microscope. One exemplary image is shown. The scale bar represents 10 μm.
[0191] Figure 8: Cells from patients harboring CCDC40 mutations in ALI cultures at the time of air lift tdTomato mRNA / LF111 or CC at a dose of 3 μg / insert for 18 d The ALI cultures were transfected with either DC40 mRNA or LF92. During the experiment, the cells were maintained in medium G. Transfection (TF) was performed once a week for 4 weeks. (=4xTF). ALI from healthy controls was used as a control. CCDC40 mRN ALI membranes treated with A and tdTomato mRNA were cut at 20 μm and stained with anti-CCD C39 (1:200, red), anti-acetylated tubulin (1:10.000, green) and Stained with DAPI (blue). Photographs were taken with a confocal microscope. One exemplary image is shown. Magnification: 40x.
[0192] Figure 9: CCDC39 protein in HEK-293 and BEAS-2B (110 kDa) expression, 6 and 24 hours after transfection. 1.4x10^5 HE K-293 cells and 3.5x10^5 BEAS-2B cells in 6-well plates Seed and express CCDC39-RNA (ETH047T02, minimal 5'UTR, Lipo transfectamine MessengerMax; ratio 1:1.5) After 6 and 24 hours, the cells were treated with M-PER and Triton® X- 50 μg of protein lysate was used for Western blot analysis. As controls, non-transfected (UT) and EGFP-transfected cells were used. of lysate was used. High dose = 0.5 μg / cm 2 , low dose=0.25μg / cm 2 .
[0193] Figure 10: CCDC39 protein (110 kDa) expression in untreated ALI cultures. Two inserts The axonal extraction protocol was used to extract 30, 10 and 5 μL of protein solution. The digest was used for Western blot analysis. Active Area: Insert 39.9 = 71.25%, Insert 41.2 = 59.88%
[0194] Figure 11: CCDC39 protein in 16HBE14 after proteasome inhibitor treatment (11 0kDa) formula. 6.0x10^5×16 HBE14o cells seeded in a 6-well plate and CCDC39-RNA (Lipofectamine MessengerMax; After 6 hours, the cells were lysed with M-PER buffer. 20 μg of protein lysate was used for Western blot analysis. Lysates from untransfected (UT) and EGFP-transfected cells were used. High dose=0.5μg / cm 2 , low dose=0.25μg / cm 2 RNA:ETH047T 02:Minimal 5'UTR, ETH047T03:TISU, ETH047T04:CY BA, ETH047T05:SP30.
[0195] Figure 12: CCDC after 16HBE14 treatment with proteasome inhibitors 39 protein (110kDa) formula. 6.0x10^5 16HBE14ocell 6 Seed into well plates and inoculate with CCDC39-RNA (ETH047T03, TISU 5 'UTR, Lipofectamine Messenger Max; ratio 1:1.5) After 24 hours, cells were lysed with M-PER buffer. Protein lysates were used for Western blot analysis. Lysates of UT and EGFP transfected cells were used. High dose = 0.5 μL g / cm 2 , low dose=0.25μg / cm 2 .
[0196] Further aspects and advantages of the present invention are described in the following examples, which are given for illustrative purposes only. Each publication, patent, or other reference cited in this application is provided for the purposes of illustration only and not for the purposes of limitation. , patent applications, or other documents are incorporated herein by reference in their entirety. EXAMPLES
[0197] Methods and materials for use in the present disclosure are described herein; Other suitable methods and materials known in the art may also be used. Materials, Methods, and Practice The examples are illustrative only and are not intended to be limiting.
[0198] I. Materials and Methods Materials, equipment, software, and test systems used The materials are listed in Table 4.
[0199] [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5]
[0200] The devices are listed in Table 5.
[0201] [Table 5]
[0202] The software is shown in Table 6.
[0203] [Table 6]
[0204] The test systems are listed in Table 7.
[0205] [Table 7]
[0206] (I. Underwater cell culture) 1.Culture The cell lines were cultured in a cell incubator at 37°C and under a humidified atmosphere with 5% CO2 content. All reagents and solutions were heated to 37°C in a water bath prior to use.
[0207] Confluent cells (approximately 90%) were first cultured in 20 mL of DPBS (w / o Mg 2+ / C a 2+ ) to remove dead cells. To detach the cells, 2 mL of trypsin was added. A 0.05% EDTA solution was added per flask. Cell detachment then occurred. The cells were incubated at 37°C until trypsin was removed using 8 mL of each medium. Since LHC-9 medium is almost serum-free, trypsinization was inactivated. Add at least an equal volume of trypsin inhibitor to the isolated BEAS-2B cells to inhibit trypsin synthesis. Then, to remove the trypsin inhibitor again, the cell solution was rotated at 1100 rpm ( The pellet had to be centrifuged at 37 °C for 5 min at 100 rpm. The pellet was then dissolved in medium. For passaging, the cells were split into different ratios according to the following specifications:
[0208] HEK 293 (DSMZ number: ACC305) This established cell line was derived from a primary human fetal mouse model transformed with adenovirus type 5 (AD5). The cells were derived from kidneys. They were then stored in Dulbecco's modified Eagle's medium (DMEM)-10% heat-inactivated ( hi) Fetal bovine serum (FBS) and 1% penicillin / streptomycin (P / S The cell line was split twice weekly. Ta.
[0209] RPMI 2650 (DSMZ number: ACC207) This cell line originated from pleural effusion in a 52-year-old man with undifferentiated squamous cell carcinoma of the nasal septum. It was selected because of its similarity to the epithelioid ciliary morphology and bronchiolar epithelium. Modified Eagle Medium (DMEM) - 10% heat inactivated (hi ) Fetal bovine serum (FBS) + 1% penicillin / streptomycin (P / S) + 1x non-essential The cells were cultured in GlutaMAX™ supplement containing essential amino acid solution (NEAA). This cell line was split once or twice a week.
[0210] BEAS-2B (ATCC number: CRL9609) BEAS-2B cells were derived from normal bronchial epithelium obtained from autopsies of non-cancerous individuals. The cells were then infected with a replication-deficient SV40 / adenovirus 12 hybrid and cloned. The culture medium used was LHC-9 modified with w / o additives. was also split once or twice a week, depending on the confluence.
[0211] The flask used for BEAS-2B cells was resuspended in 0.01 mg / mL of LHC-9. Fibronectin, 0.03mg / mL collagen and 0.01mg / mL bovine serum albumin The mixture was coated with albumin. 2 At a rate of 0.2 mL per surface area After that, incubation at 37°C for at least 6 hours was required. Before adding the cells, the flask was 2+ / Ca 2+ Dulbecco's Phosphate Buffered Saline Free Washed three times with saline.
[0212] 2. In vitro transcription To generate a template for in vitro transcription, the circular plasmid was digested with BstBI. The fragment was linearized by limited digestion and further purified by chloroform-ethanol precipitation.
[0213] The mRNA was digested with T7 RNA polymerase, inorganic pyrophosphatase, and RNase Standard in vitro transcription mix containing inhibitors (modified triphosphate nucleases as indicated) Co-transcriptional capping was achieved using the ARCA cap analog For in vitro transcription of chemically modified RNA, 7.5% of cytidine-5'-triphosphate with 5-iodocytidine-5'-triphosphate Substitute 30% of uridine-5'-triphosphate with 5-iodouridine-5'-triphosphate. phosphate (Jena Biosciences) (see e.g. SEQ ID NO:1) In another chemically modified RNA production setup, 3% cytidine-5'-triphosphate 15% of uridine-5' was replaced with 5-iodocytidine-5'-triphosphate. -triphosphate was converted to 5-methyl-uridine-5'-triphosphate (Jena Biology osciences) (see, for example, SEQ ID NO: 2). Purification was performed by ammonium chloride precipitation, followed by a washing step with 70% ethanol. .
[0214] Residual uncapped mRNA was dephosphorylated using the Quick Dephosphorylation Kit. followed by purification by ammonium acetate precipitation, followed by 70% ethanol. A washing step was then performed to remove the eluate, followed by ultrafiltration using a filter with a 100 MWCO cutoff. .
[0215] The mRNA was further polyadenylated using poly(A) polymerase. A was purified by ammonium acetate precipitation followed by a washing step using 70% ethanol and 10 The product was purified by ultrafiltration using a filter with a 0 MWCO cutoff. was determined to be 100-250 nucleotides by capillary gel electrophoresis. .
[0216] In particular, the CCDC40 mRNA construct investigated in this experiment contains a 5'ARCA cap and and PPA, including: Ethris' minimal UTR (ETH031 06;T06;SEQ ID NO:5), TISU with 5'UTR but without 3'UTR (E TH03107; T07; SEQ ID NO: 6), with hAg 5'UTR but without 3'UTR (ETH03108; T08; SEQ ID NO: 7), which does not contain the CYBA 5' and 3' UTRs (ETH0310T0; T09; SEQ ID NO: 1), and 5 from human CMV IE9 ’UTR and with the 3’UTR from human growth hormone (ETH031T0;T10; Sequence number 8).
[0217] 3. Transfection Transfect cells to provide at least 90% confluency. Cells were seeded in 6-well plates 24 h prior to incubation. Cell numbers were determined based on readout time point and cell type. Therefore, they differed (compare Table 8).
[0218] [Table 8]
[0219] Transfection was performed using enhanced green fluorescent protein as a transfection control. Different CCDC40 mRNAs, as well as the mRNAs encoding the photoprotein (eGFP), Transfection was performed using the A construct. Transfection was performed using Sigma-Aldrich 2000, the culture medium was replaced, and the cells were The optimal conditions were provided. The lipoplexes were prepared by mixing the mRNA / WFI mixture and the Lipofe ctamine® 2000 / medium mixture was required. 125 μL of mRNA was added to the Liposomes, as the mRNA had a stock concentration of 1 μg / μl. Ofectamine® 2000 was used at a volume ratio of 1:2. A concentration was used and the mixture was adjusted accordingly (see example pipetting scheme). (See Table 9 for details.)
[0220] [Table 9]
[0221] After preparing both mixtures, the mRNA / WFI mixture was incubated with Lipofectamine ( Add to the 500 mg / medium mixture and incubate the solution for ≥5 minutes. It was added dropwise to the seeded cells. To obtain a better survival rate of the cells, An additional medium exchange was performed 4 hours after infection.
[0222] 4. CCDC40 Western Blot a. Sampling for Western Blot For cell lysis, remove the culture medium from the transfection and lyse the cells in DPBS ( Mg 2+ / Ca 2+ without any washing, then Corning® Cell S The cells were scraped using scrapers. The cells were then lysed in 100 μL of lysis buffer [10x Trit on(R) X-100 lysis buffer (250mM Tris-HCl, 1% Tri ton® X-100, pH: 7.8) was adjusted to 1x in WFI and After supplementing with the enzyme inhibitor cOmplete, the samples were frozen at -20°C and lysed. Ta.
[0223] Total protein concentrations were determined using the Pierce™ BCA Protein Assay Kit (BCA Assays were performed according to the manufacturer's protocol. Briefly, a 1:50 dilution of BCA Working Reagent (WR) was prepared. Transfer 100 µL of WR per well to a 96-well plate (flat bottom, clear) and add 200 µL of WR per well. The final step was a 30 minute incubation at 37°C. The data was analyzed using the Agellan™ software, Tecan Infinite The plates were measured using a Eppendorf (Registered Trademark) 200 PRO plate reader.
[0224] b. Preparation of NET-gelatin
[0225] [Table 10]
[0226] c. SDS-PAGE and Western Blot Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed. To perform the assay, lysates were diluted with 5 μL of LDS sample buffer (4x) and 2 μL of The samples were mixed with reducing agent (10x) and then cooled in a Thermomixer® C. Heat to 70°C for 10 min and 350 rpm. 7 μL of marker (Precision n Plusprotein™ Dual Color Standards The first pocket of each gel was filled, allowing for subsequent accurate protein size estimation. The gel tank was then connected to a power supply (Power PAC 300) at 1 A for 30 minutes. The cassette was then opened with a spatula and the gel was transferred to the blotting station. Ta.
[0227] Transfer System (Transfer-Blot) Turbo™ Transfer System, 30 min, 25 V, 1A) and a suitable membrane (Transfer-Blot Turbo Transfer Pack Mini 0.2μm PVDF) was applied to the blot according to the manufacturer's instructions. By scrolling a roller over the "sandwich", the Any air bubbles that may interfere with protein transfer were eliminated. The membrane was then placed in NET-gelatin and shaken on a plate shaker for 60 minutes. The cleavage was performed at 100 kD band to identify CCDC40 and glyceraldehyde-3-phosphatase. Hydrogenase (GAPDH) was detected simultaneously. The antibodies were applied to NET-gelatin (6 mL Anti-CCDC40 1:2000, GAPDH 1:10 in 10 mL NET-gelatin 000) and the membranes were incubated overnight at 4°C on a plate shaker. DH served as a loading control. The list of antibodies used is shown in Table 11. The next day, the membrane was washed with N Non-specifically bound or residual antibodies were removed by washing three times for 10 min with ET-gelatin. The secondary antibody goat anti-rabbit IgG-HRP was diluted 1:10,000 in NET-gelatin. After 60 min of incubation on a plate shaker at room temperature (RT), the membranes were incubated for 2 h at RT. Washed three times for 10 min with ET-gelatin. Horseradish peroxidase-HRP-conjugated secondary antibody The body can be detected via molecular imaging (ChemiDoc™ XRS system). Therefore, 5 mL of Luminata Crescendo Western HRP Substrate was added onto the gel and incubated for 5 minutes. The last photo that was not overexposed was merged with the colorimetric photo and then the Image Lab(TM) The software then visualized the bands using Image Lab™. The strength was measured.
[0228] [Table 11]
[0229] (II. ALI culture) 1. Sampling of human respiratory epithelial cells (hRECs) a. Nose brushing The RPMI medium was heated to room temperature and the brush was moistened with sterile isotonic saline. A Celletta brush cell collector was applied to the patient. After asking him to do so, he had to hold his head by sitting on a chair with his head against the wall. The brush was quickly brushed over the inside and superior side of the inferior meatus several times using rotary and linear movements. Immediately after removing the rats, place them in a collection tube (1 The brush was then vigorously shaken at least 40 times in the tube to remove the stain. The cells were detached from the brush.
[0230] b. Stationary culture The tube was spun at 900 rpm for 5 min at room temperature. The supernatant was discarded and the pellet was lysed with UG. Culture medium [DMEM / Ham's F-12 1:1, 5 mL of sterile 100x antibiotic tics / mycotics and 10 mL of sterile Ultroser G]. 5 mL of medium was used for the T25 and 25 mL for the T75 flask.
[0231] After transferring the cells to a cell culture flask, the cells are incubated in a humidified incubator containing 5% CO The cells were incubated overnight at 37°C in 100% CO. Cells should not have attached after 20-24 hours. The UG medium was changed three times a week (Monday, Wednesday, and Friday).
[0232] 2. Generation and transfection of ALI cultures a. Coating of transwell inserts (0.33 cm 2 ) The following plates were used for ALI culture: transparent polyester membrane (0.4 μm pores, 6. Corning Transducer with 5mm diameter inserts (24-well plate) Dilute rat tail collagen 1:5 in acetic acid and add 250 μL to the tip of each insert. The plate was incubated overnight at room temperature, after which the remaining liquid was removed using a cold pipette. The plate was then aspirated with a suction and the plate was then allowed to dry with the lid open for at least 5 minutes (sterile). Place the insert in DPBS (w / o Ca 2+ / Mg 2+ ) and then overnight at room temperature. Allow to dry (sterile). Inserts were stored at 4° C. for up to one month.
[0233] b. Cell proliferation of hREC as a submerged culture (static culture) Cells were resuspended in 15 mL of pre-warmed UG media every 2-3 days (Monday, Wednesday, and Friday). To prevent damage to the collagen layer and detachment of cells, fresh medium was added to the collagen layer. Care had to be taken not to add the cells directly onto the gel layer. The cells were transferred to the ALI filter either immediately after incubation or immediately after the collagen layer began to detach. (After approximately 3 weeks, cultured in water).
[0234] c. Preparation of medium G Different ALI media were tested, but the self-made medium G is preferred.
[0235] This medium was prepared for a week and needed to be stored at 4°C. The batches were then transferred to the The cells were frozen in aliquots based on size. Table 2 shows the composition of medium G.
[0236] d. Seeding and airlift of hREC (ALI culture) 1. Aspirate the UG medium and replace with washing medium [DMEM / Ham's F-12 1:1 (1x Sterile antibiotic / antimycotic)] or DPBS (w / o Ca 2+ / Mg 2+ ) once. R 2. For homemade rat tail collagen coated flasks: Add 9 mL (1x) of collagenase to dissolve the collagen layer and incubate at 37°C for 45-50 minutes. Incubate for 60 minutes b. Transfer the cells to a 15 mL Kolnik tube and centrifuge at 1000 rpm for 5 minutes at room temperature. Isolate c. Wash the cells with washing buffer (1000 rpm, room temperature, 5 min). d. Add 2 mL of Trypsin-EDTA (1x) and gently rub to detach the cells. Pipette up and down and incubate the cells at 37 °C until cell clusters break up. Shake the keratin until smooth (approximately 5 minutes). For collagen-coated flasks purchased from Gibco: a. 3 ml of trypsin-EDTA (1x) was added to the cells until they detached (approximately 5 min). Add to culture flask 3. Trypsinize by adding 0.5 mL of FBS and 5 mL of wash medium. Stop the 4. Transfer the cells to a 15 ml Falcon and wash the cells with washing medium (1000 rpm, room temperature, Wash twice with 500 mM NaCl for 5 min. 5. Resuspend the pellet in an appropriate amount of ALI medium (1–2 mL, depending on pellet size). Suspend and count cells using a cell counter 6. Add 250 μL of cell suspension (400,000 cells / mL) to the basolateral side of the 500 μL Add L of ALI medium to each collagen transwell coated with 7. Incubate the cells overnight at 37°C in a humidified 5% CO2 incubator. do Days 3-5: ALI-expansion 8. Check inserts consistently under a microscope 9. Feed cells with ALI medium daily until 80–100% confluence (3–4 days) ALI differentiation 10. Airlift cells when they reach 80-100% confluency a. Aspirate the ALI medium from both the apical and basolateral sides. b. Add 500 μL of fresh ALI medium to the basolateral compartment c. Incubate the cells at 37°C in a humidified 5% CO2 incubator. R 11. Once a week, wash the cells with pre-warmed washing medium (tip) and rinse the cells with ALI medium. is provided every 2-3 days (or Monday-Wednesday-Friday)
[0237] e. Transfection of hRECs The formulation (LF111-mRNA) was administered at 3 μg / insert (=9 μg / cm 2 ) final concentration The insert was then diluted in 2% sucrose until the mucus was removed. 0 μL of DPBS (w / o Ca 2+ / Mg 2+ ) and then incubated at 37°C (epithelial AL I) or 200 μL of DPBS (w / o Ca 2+ / Mg 2+ ) for 20 minutes. The cells were then incubated at room temperature for 5 min before transfection. DPBS (w / o Ca 2+ / Mg 2+ ) by gentle suction without damaging the epithelium. Immediately after the mucus wash, the cells were washed again with WFI (100 μL) and microdissected. Amount of DPBS (w / o Ca 2+ / Mg 2+ ) was removed. 25 μL of the formulation was After 6 h of incubation, Then, remove the carrier and resuspend the cells in 200 μL of DPBS (w / o Ca). 2+ / Mg 2+ ) in 1 The cells were washed twice and the cultures were maintained as ALI without fluid on the apical side.
[0238] 3. Readout assay Various readout assays are used. LDH measurement and NucGreen assay To investigate the toxicity-related effects of transfection, ciliary beat frequency (CBF ) was necessary to investigate the pattern of ciliary beating in terms of beating frequency and percentage of ciliary area. When cilia beating directs directional flow, this is called mucociliary clearance (MCC). Assays can be used to study CCDC40, its heterodimer partners, Immunofluorescence (IF) for CCDC39 and the ciliary marker acetylated α-tubulin ) staining to detect CCDC40 protein or its partner CCDC3 after treatment. We further investigated whether GAS8 and DNALI1 could be detected in cilia. We stained for proteins of the dynein regulator complex (DRC), such as CC. The ciliary axon is anchored by DC40 / CCDC39, and CCDC40 / CCDC39 is positively associated with the ciliary axon. It exists only if properly incorporated.
[0239] a. LDH measurement LDH concentrations were measured using Pierce™ Lactate Dehydrogenase Cytotoxicity was measured using the Cytotoxicity Assay Kit. This procedure was performed according to the manufacturer's instructions. The ALI incubation is performed as described in the protocol. 100 μL of DPBS (with MgCl) for 30 min at 25°C. 2+ / Ca 2+ Using a ) on the top surface Incubated with 50 μL of LDH reaction mixture and 50 μL of incubation The media was mixed using a 96-well format, 50 μL of stop solution was added, and incubated at room temperature. The plates were incubated at 4°C for 30 min protected from light. The absorbance of the formazan was measured using a microplate reader. Reader (TriStar2 Multimode Reader LB 942) The 680 nm value was used as the background Subtraction from 490 nm was performed for normalization. Duplicate measurements were performed for each insert.
[0240] b. Ciliary body frequency (CBF) measurement Ciliary body beat frequency (CBF) analysis of hRECs was performed using high-speed video microscopy and Sisson- Ammons video analysis. Minitube SC300 heating device. By maintaining the temperature at 36°C, the ELWD 40x S Plan is kept under physiological conditions. A Megaplus camera model was attached to an inverted phase contrast microscope equipped with a Fluor objective. Video (125 fps, 640x480 pixel resolution) recorded using the ES 310 Turbo Recorded.
[0241] c. Mucociliary clearance assay (MCC, fluorescent beads) ALI medium and DPBS (w / o Ca 2+ / Mg 2+ ) to room temperature and place it in the Plates were heated to 37° C. The ALI inserts were transferred to new plates and incubated with pre-warmed ALI medium (alternative D PBS with Ca 2+ / Mg 2+ The tip was washed twice with 100 μL of ALI medium. After addition of medium to the apical compartment, 20 videos (magnification 40x, Ph2) were recorded per insert. A comprehensive impression of the insertion was obtained (SAVA software). The offspring were then placed in DPBS (w / o Ca 2+ / Mg 2+ ) for at least 1 min. Vortex for 10 min, add 10 μL of the particle dilution to 100 μL of ALI medium, and vortex for 1 min. The beads were then mixed and 110 μL was added to the apical compartment. It was important to vortex before each step. In addition, to avoid bleaching, keep the mixture in a dim light. It was necessary to work in bright light.
[0242] The flow of fluorescent particles was analyzed using NIS-Elements Basic Research software. The images were recorded using a 20x magnification microscope while exciting particles with a 488 nm laser. Movement was recorded for 20-30 s using ON (Ph1). Exposure time was 100 s. The frame rate (fps) had to be adjusted. For 7.5 fps, the exposure time was The frame rate was set to 100 ms, and the frame rate was set to 50 ms from 15 fps. Analysis was performed with SAVA (20x magnification, Ph1) to visualize ciliary movement and 3D structure of the cell layer.
[0243] For evaluation and data analysis, we used the Nikon NIS Elemets AR Sof tware, NIS PLUG-IN<ADVANCED 2D TRACKING> <ar>(See NIS Elements AR Tracking Module above) ) to use the
[0244] d. IF of ALI cultures Embedding of ALI cultures Prior to membrane preparation, the ALI inserts were resuspended in DPBS (w / o Mg 2+ / Ca 2+ , 200μL, The mucus was removed by washing twice at 4 °C for 1 min at room temperature. The following membrane preparation was performed according to the following protocol (see below). The procedure will be carried out in accordance with the following:
[0245] Using a scalpel or syringe, cut out the transwell filter membrane and then remove the membrane. 3 ml of DPBS (Ca 2+ / Mg 2+ The membrane was then transferred to a Petri dish containing 100 mL of PBS. and embedded in Shandon Cryomatrix™ freezing embedding medium (medium size). The cryomold was prepared using a 100% 100% 100% 100% 15 ... The membrane pieces were placed in a cryomatrix before incubating the pellet on dry ice. The cryomolds were placed parallel to each other. Before cutting in the cryostat, the cryomolds were frozen at −80 °C. Store at RT for at least 2 hours.
[0246] Cleavage of the ALI membrane The ALI membrane embedded in Shandon Cryomatrix™ was cryopreserved. The sections were cut using a Microm HM560. The plates were pre-cooled to -20°C (-21°C table and -25°C chamber) (2 days before cutting). (~3 hours before incubation). Transform the ALI membrane containing the cryomods from -80°C to -20°C for at least 1 hour. The membrane was cut at 20 μm depending on the membrane handling conditions. Transfer to a Superfrost Ultra Plus slide and dry at room temperature for at least 1 hour. The cells were dried and stored at -80°C overnight or at -80°C until use.
[0247] Staining procedure For antibodies applied, see Table 12. Day 1: 1. 1xDPBS (Ca 2+ / Mg 2+ ) for 5 minutes at room temperature 2. Fixation: Fix the tissue in 4% PFA / 1xDPBS (Ca) at room temperature. 2+ / Mg 2+ ) 15 minutes 3. Wash 3x DPBS (Ca 2+ / Mg 2+ )(2x fast, 1x5 minutes) 4. Transparency: a. 0.5% Triton® X-100 for 5 minutes or b. 0.2% Triton® X-100 for 10 minutes (if used) (depending on the antibody used) 5. Prepare 3x DPBS (Ca) at room temperature 2+ / Mg 2+ ) (2x Quick, 1x 5 min) Purify 6. Blocking: 5% normal goat serum + DPBS (Ca 2+ / Mg 2+ ) at 2%BS A, or DPBS (Ca 2+ / Mg 2+ ) with 5% skim milk → leave at room temperature for 2 hours 7. 200 μl of primary antibody at 4°C overnight Day 2: 8. DPBS (Ca 2+ / Mg 2+ ) for 45 minutes (3x15 minutes) 9. Secondary antibody: 200 μL for 1 h at room temperature 10. Soak the cells in DPBS (Ca) for 10 min at room temperature in the dark. 2+ / Mg 2+ ) Hoechst33 342 1:1000 11. DPBS (Ca 2+ / Mg 2+ ) for 6x5 min. 12. Mounting coverslips with Dako Antifade
[0248] [Table 12]
[0249] e. Airbrushing of ALI cultures Differentiated ALI cultures were generated using an airbrush model. The protocol was adapted from Cresp in et al. 2011(Approaches to Study Differ entiation and Repair of Human Airway Epi It was established after thelial Cells.
[0250] Cells were incubated in pre-warmed DPBS (with Mg 2+ / Ca 2+ ) for a short time at the tip. A compressor connected to the airbrush rotates the airbrush, which in turn spins a small wheel. Therefore, 1kg / cm 2 I set it to . The airbrush stays at a constant value, so at some point You may need to work for a while. Next, put a small litho gun on the airbrush. The sieve was then placed in DPBS (Mg 2+ / Ca 2+ ) and insert into a new plate without basal medium. The airbrush was started by pushing it to the first pressure point, and the compressor pressure was kept constant. Then, place the airbrush vertically on top of the insert and press the airbrush The lever of the DPBS(Mg 2+ / Ca 2+ ) (The apical end of the insert was then immersed in pre-warmed DPB.) S(Mg 2+ / Ca 2+ ) and the inserts were transferred to fresh, 100% PBS-compatible 100% ethanol ... The wound was checked by microscopic observation. It was found to be too small (the area of the insertion If the wound is only slightly detached (less than 1 / 3), repeat this procedure. The cultures were incubated at 37°C in a humidified atmosphere with 5% CO2 and cultured as ALI. did.
[0251] (III. Labeled CCDC40 mRNA) The mRNAs under study are shown in Table 13.
[0252] [Table 13]
[0253] a. Cell culture HEK-293 cells were cultured in MEM GlutaMAX™, 10% FBS, 100 U The cells are cultured in 1 ml P / S (=culture medium) at 37°C and 5% CO2.
[0254] Before seeding, cells are washed with DPBS and detached using trypsin. After trypsinization Inactivate trypsin using culture medium containing FBS. Culture medium of 100 ml is used. Centrifuge at 1100 x g for 5 minutes and resuspend in normal growth medium. Afterwards, the cells were counted using a Countess Cell Counting Device. Count.
[0255] b. In vitro transcription To generate a template for in vitro transcription, the circular plasmid was digested with BstBI. The fragment was linearized by limited digestion and further purified by chloroform-ethanol precipitation. The mRNA is digested with T7 RNA polymerase, inorganic pyrophosphatase, and RNase inhibitors. The plasmid was produced using a standard in vitro transcription mix containing a co-transcriptional capping agent. Blocking of the RNA was achieved by the addition of an ARCA cap analogue. For in tro transcription, 7.5% cytidine-5'-triphosphate was added to 5-iodocytidine 30% uridine-5'-triphosphate was added to 5-iodophenyl phosphate. Douridine-5'-triphosphate was substituted for each of the other SNIM® In the RNA production setup, 3% cytidine-5'-triphosphate was replaced by 5-iodocytidine- 15% of the uridine-5'-triphosphate is 5-methyl- The remaining template DNA was purified by DNase The mRNA was then purified by ammonium acetate precipitation, followed by A washing step was performed with 70% ethanol.
[0256] Residual uncapped mRNA was dephosphorylated using the Quick Dephosphorylation Kit. followed by purification by ammonium acetate precipitation, followed by 70% ethanol. A washing step was then performed to remove the eluate, followed by ultrafiltration using a filter with a 100 MWCO cutoff. .
[0257] The mRNA was further polyadenylated using poly(A) polymerase. A was purified by ammonium acetate precipitation followed by a washing step using 70% ethanol and 10 The product was purified by ultrafiltration using a filter with a 0 MWCO cutoff. was determined to be 100-250 nucleotides by capillary gel electrophoresis. .
[0258] c. Seeding, transfection and readout Cells were plated in 96-well black microplates (25 cells per well) 24 hours prior to treatment. 24 hours after seeding, fresh medium was added to each well (10 The mRNA was then transferred to Lipofectamine at a ratio of 1:1.5 (w / v) RNA to Lipofectamine. Pofectamine® MessengerMAX™ 250ng / 96 well (758ng / cm 2 )eGFP-CCDC 40 (ETH031T28 or ETH031T30) or HA-CCDC40-T2 A-tdTomato (ETH031T26) mRNA was used. All RNAs were 1 ml For lipoplex formation, the mRNA was dissolved in water and had a stock concentration of 100 µg / mL. Most diluted. Lipofectamine® MessengerMAX (trademark) was diluted with SFM (serum-free medium) and mixed by pipetting. After incubation for 1 min, the RNA solution was diluted with Lipofectamine® Me Add to the ssengerMAX™ solution, mix, and incubate for an additional 5 minutes at RT. The mixture was then diluted 2-fold with SFM, and the Lipoplex solution was added to the wells. In Table 14, an example for one RNA was calculated.
[0259] [Table 14]
[0260] Transfection efficiency was assessed by fluorescence in situ hybridization 6 and 24 hours after transfection. They were examined by light microscopy and photographed at 10x magnification.
[0261] (IV. CCDC39) The mRNA under study (ETH047T02; SEQ ID NO: 12) encodes hCCDC39. , containing the Ethris minimal UTR. 15% of the phosphates were 5-methyl-uridine-5'-triphosphate and 15% were cytidine-5'-triphosphate. A total of 3% of the triphosphates were replaced by 5-iodo-cytidine-5'-triphosphate. The antibodies used are shown in Table 15.
[0262] [Table 15]
[0263] 1. CCDC39 transfection and Western blot in submerged cell culture to a. Cell culture BEAS-2B cells were cultured in LHC-9 medium in coated flasks. For details, see I1 above. The experiment was performed on uncoated plates. went.
[0264] HEK-293 cells were cultured in heat-inactivated FBS and penicillin / streptomycin ( The cells were cultured in MEM GlutaMax medium supplemented with 100 mM P / S).
[0265] Before seeding, cells were washed with DPBS and detached using trypsin. After trypsinization Trypsin was inhibited with trypsin inhibitor for BEAS-2B or with trypsin inhibitor for HEK-293. The cells were inactivated with either FBS-containing culture medium or culture medium containing FBS. or more volumes of trypsin inhibitor / culture medium were used. After centrifugation for 5 min and resuspension in normal growth medium, cells were cultured on the Countess Cell The cells were counted using a Counting Device. Considering the rule plate format, 5.0x10 5 Seed BEAS-2B cells and 1. 4x10 6 Seeding HEK-293 cells was obtained.
[0266] b. Transfection Cells were seeded at the respective densities 24 hours before treatment. 24 hours after seeding, 2 mL of Fresh medium was added to each well. mRNA was incubated at 1:1.5 (w / v) RNA to lipofuscin. Lipofectamine® MessengerMA All RNAs were transfected at a stock concentration of 1 mg / mL. For lipoplex formation, mRNA was diluted in aqua bidest. Lipofectamine® MessengerMAX™ The solution was diluted with SFM and mixed by pipetting. The solution was incubated at room temperature for 10 minutes. Afterwards, the RNA solution was transferred to Lipofectamine® MessengerMA X™ solution, mixed, and incubated for an additional 5 minutes at room temperature. The poplex solution was added to the wells. The examples are calculated for one 6-well plate.
[0267] [Table 16]
[0268] c. Cell lysis To obtain optimal cell lysis, two different lysis buffers (Triton® The results are shown in Table 1. The lysis buffer (X-100 buffer and the commercially available lysis buffer M-PER™) was compared. Contains protease inhibitors cOmplete, Complete, and 40 μL / mL D The cells were then supplemented with Nase I solution (in a 23:1:1 mixture). The cells were seeded on a 100-well plate and treated for 6 and 24 hours. After treatment, the cells were harvested. The plate was washed once with 1 mL of DPBS to remove the cells from the plate. Then, add another 1 mL of DPBS, scrape the cells off the plate, and transfer them to an Eppendorf tube. To remove the DPBS, the cells were centrifuged at 6250 x g for 2 minutes at 4°C. Cell lysis was performed by adding 200 μL of the respective buffer. To ensure complete lysis, cells were incubated on ice for 30 min. After lysis, BCA assay was performed. Perform the assay using a BCA protein assay kit according to the manufacturer's instructions. , with the following modifications, total protein concentration was determined: 200 μL of working reagent was added to 5 μL of cell lysate. ● Samples and standards were measured in triplicate. Rotate the plate at 450 rpm for 30 minutes before incubating the samples at 37°C for 30 minutes. Shake for 2 seconds
[0269] d. Sample preparation Samples were diluted with 5 μL of Bolt® LDS sample buffer and 2 μL of Bolt® LDS sample buffer. The samples were mixed with a reducing agent and then heated at 70°C for 10 minutes before being subjected to SDS-PAGE. 30 μg of total protein was used for SDS-PAGE and diluted with 4 to 12 mL of Volt™. % SDS-PAGE gel, 10 wells were used.
[0270] e. SDS Page and Blotting method Trans-Blot® Turbo™ System Transfer SDS-PAGE was performed at 200 V for 40 min. The procedure was carried out for 30 minutes using the nsBlot® Turbo™ transfer system.
[0271] f. Antibodies and blocking methods After transfer, the membrane was blocked for 1 h at room temperature using NET-gelatin as a blocking reagent. The antibody HPA035364 from Atlas Antibodies was used for the detection of CCDC39. The antibody ab8227 from Abcam was used to detect actin. Before adding the antibody, The membrane was cut at approximately 60 kDa. The membrane was incubated with the primary antibody overnight at 4°C. Room temperature After washing three times (10 min each) with blocking solution, horseradish peroxidase-conjugated dimers were added. The secondary antibody was added (diluted 1:20 000) for 1 h at room temperature. The membrane was blotted every 10 min at room temperature. The beads were washed again three times with the blocking solution.
[0272] g. Chemiluminescence signal development The signal was generated using a chemiluminescent substrate kit (Luminata Cr, depending on the intensity of the signal). escendo, Classico or Forte Western HRP Substrate) and and visualization using the ChemiDocTM MP System.
[0273] 2. Western Blot of Endogenous CCDC39 in Differentiated ALI Cultures a. Cell lysis Add 250 μL of ALI lysis buffer (see Table 17 for composition details) per insert. The mixture was incubated on ice for 15 minutes. ALI lysis buffer was pipetted back and forth to the ends of the tubes. After rinsing each insert with 150 μL of ALI lysis buffer, samples were thoroughly vortexed. At this step, the samples may optionally be stored at -20°C until further processing. do.
[0274] [Table 17]
[0275] b. Isolation of axonemal lysate from whole cell lysate The sample was added to a Lysing Matrix A tube (after washing the tube, (The garnet was removed by washing with 70% EthOH.) The tube was fixed and The tubes were frozen in liquid nitrogen for 20 seconds while moving. 4 (HOM-1) and set it to 6.5 m / s, 3 x 1 min. Then, insert the tube After condensation on ice for 15 min, the liquid was transferred to a fresh Eppendorf tube and incubated at 1100 r The supernatant was transferred to a new Eppendorf tube and incubated at 4 °C for 20 min. Retents and supernatants were stored at -20°C until further processing.
[0276] c. Preparation of axonemal extract lysate: High-salt extraction of ciliary axonemal proteins Each pellet was resuspended in 50 μl of MMRB + 0.1% Triton® X-1. 00 (MMRB + 0.1% Triton® X-100) Composition Details See Table 18 for details) and incubated on ice for 30 minutes (with occasional gentle shaking). After spinning at 14,000 rpm for 10 min at 4°C, the supernatant was Transferred to a new Eppendorf tube and stored at -20°C until further processing.
[0277] [Table 18]
[0278] [Table 19]
[0279] d. Preparation of lysates for Western blot The samples were thawed on ice and 30 μl of the sample was transferred to a new Eppendorf tube. Before heating the samples at 70 °C and 350 rpm for 10 min, add 1 μL of LDS sample buffer and 1 μL of PBS. 5 μl of 0× reducing agent was added. 5, 10 and 30 μl per well were added using Bolt® ) Applied to 10 wells of a 4-12% SDS-PAGE gel.
[0280] e. SDS Page and blotting methods: See IV 1e
[0281] f. Antibodies and blocking methods: See IV 1 f.
[0282] g. Chemiluminescent signal generation: See IV 1g
[0283] (II. Results) CCDC40 expression was measured at 6, 24, 48, and 72 h after transfection. and after 144 hours in HEK293 cells. 0.2 / 0.05x10 6 Seed and Lipofect the cells in 6-well plates Various CCDC40 constructs (2.5 μg / 9) were incubated with amine® 2000. .5cm 2 The cells were transfected 24 h after seeding with 100 μg / ml of 1000 μl ... The CCDC40 mRNA constructs were T06 to T10 (SEQ ID NO: 1, and SEQ ID NO: 5 to SEQ ID NO: 8) at 6, 24, 48, 72 and 144 hours after transfection. After cell lysis, 50 μg of total protein lysate was analyzed by SDS-PAGE and Western Analyzed by blot.
[0284] As can be seen in Figure 1, peak translation efficiency was observed for CCDC40 mRNA in HEK cells. It was detectable 6 hours after transfection of A.
[0285] In this case, 2x10 6 HEK293, 7.5x10 5 BEAS-2B and 5x10 5 RPMI 2650 cells were seeded in 6-well plates and cultured with SD S-PAGE and Western blot (HEK293: 50 μg, RPMI 26 Protein analysis was performed using BEAS-2B: 20μg (total analysis of BEAS-2B: 30μg). When I went there, I found Atlas Antibody (1:2000) Anti-CCDC40 An CCDC40 was detected using the antibody (HPA022974).
[0286] Here, T09 (CYBA; SEQ ID NO: 1) and T10 (human growth hormone; SEQ ID NO: 8) Human CMV IE9 and 3'UTR from BEAS-2B, RPMI26 Highest translation efficiency at 50 and 6 h after transfection in HEK293 cells It can be seen that this resulted in (Figure 2).
[0287] We then performed two experiments to examine the restoration of ciliary motility in patient-derived ALI cultures. In particular, the first experiment used undifferentiated ALI cultures (data not shown). (Ciliated cells have a deletion of exons 1 and 2, resulting in a very short position In the first experiment, differentiated ALI cultures were used, whereas in the second experiment, differentiated ALI cultures were used. In both cases, 3 μg LF92 / CCDC40 (ETH031T09; sequence no. The cells were transfected with 1) every other day for one month, a total of 16 times. High-speed video microscopy (HSVM) was performed every 24 hours, and immunofluorescence immunocytochemistry (IF-ICC) was performed. Before transfection and every 24 hours after transfection, The ciliary body beat frequency (CFB) was recorded using the SAVA software. The calculation was performed using the software. All 16 transfections (1 month) were performed. , using 40x magnification at 37° C. The mean ciliary beat frequency (CBF) is calculated.
[0288] Repeated transfection of LF92 / CCDC40 resulted in the development of fully differentiated patient-derived A CCDC40 protein was well tolerated in LI cultures. Two days later, spontaneous subcellular regions of airway epithelial cells, i.e., cilia, were detected, and ciliary motility was observed in the L Diagram of experiments with differentiated ALI cultures after F92 / CCDC40 transfection. As seen in FIG. 3, the cilia beating frequency increased to approximately 50% of the normal frequency from day 18 onwards.
[0289] Undifferentiated ALI cultures were obtained using medium G as described in the Materials and Methods section. , and transfection (TF) was initiated 18 days after airlift. Transfection of CCDC40 patient ALI cultures with 40 mRNA / LF92 ( TF) was performed once a week for 4 weeks (=4x TF). Mucociliary clearance (MCC) was , measured at 20x magnification with 0.5 μm fluorescent beads. 30 videos of different areas Photograph and analyze with Polargraph software from Nikon one week after the last TF. .
[0290] Importantly, after 4 weeks of CCDC40 mRNA / LF92 transfection We were able to detect the restoration of cilia beating in CCDC40 patients with ALI. This enabled directional particle transport as shown in Figure 4. For comparison, the control Four times more tdTomato mRNA / LF111 transfection and healthy controls Particle transport in the control case is shown in FIG.
[0291] Thus, during ciliary cell differentiation, as shown by comparison with the tdTomato control Thus, the success of CCDC40 mRNA / LF92TF in patient ALI cultures using LF92 successful ciliary growth, successful ciliary beating, successful directional particle transport, and successful transcription. Protein detection (CCDC40 + GAS8 / DNALI1 as part of the DRC complex) Furthermore, the tdTomato control insert was The infusion did not show any of the above effects.
[0292] Figure 6 shows that the control (tdTomato mRNA)-treated patients with ALI did not have a normal control. Similarly, GAS8 protein expression in axonemes after repeated ALI treatment of patients with CCDC40 mRNA Figure 7 shows the successful uptake of the protein in control (tdTomato mRNA)-treated patients. Following repeated patient ALI treatment with CCDC40 mRNA, as well as healthy controls, not present in I Figure 8 shows the successful incorporation of DNALI-1 protein into the axoneme of the control (tdTo CCDC40 m CCDC39 protein was successfully incorporated into axonemes after repeated RNA treatment of patient ALI. This shows that it was successful.
[0293] In summary, ciliary motility could not be restored to significant levels using differentiated ALI cultures. However, this was partially restored using differentiated ALI cultures.
[0294] Regarding the CCDC39 experiments, the CCDC39 protein was expressed in HEK 6 h and 24 h after transfection in -293 and BEAS-2B cells After 24 hours, the expression of β-lactamase was detected by Western blot analysis. CCDC39 (ETH047T03; SEQ ID NO: 13) is a protein that is used in 16HBE14o. The adenosine triphosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate phosphate No. 12), ETH047T04 (SEQ ID NO: 2), and ETH047T05 (SEQ ID NO: 1 A similar experiment was also conducted for 4) and the same results were obtained. As shown in Figure 12, C39 (ETH047T03; SEQ ID NO: 13) formula also contains the 16HBE14o proteasome inhibitor In the presence of seroconverting factor 1 (S1), the cytotoxicity was detectable after 24 hours.
[0295] Exemplary sequences described in this application are provided below. The present disclosure relates in some embodiments to For example, the UTR sequence shown in SEQ ID NO: 1 or 2, or a sequence at least similar to such a sequence. a sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of any of the preceding Polyribonucleotide sequences, such as mRNAs corresponding to or encoded by In certain embodiments of any of the above, the polyribonucleotide comprises a sequence of The nucleotides or polyribonucleotides may be modified (e.g., (including leutidine analogues).
[0296] SEQ ID NO:1 TIFF2024096766000037.tif159160TIFF2024096766000038.tif234163TIFF2024096766000039.tif21157
[0297] SEQ ID NO:2 TIFF2024096766000040.tif202157TIFF2024096766000041.tif141160
[0298] SEQ ID NO:3 TIFF2024096766000042.tif81160TIFF2024096766000043.tif128164
[0299] SEQ ID NO:4 TIFF2024096766000044.tif95164TIFF2024096766000045.tif82161
[0300] SEQ ID NO:5 TIFF2024096766000046.tif145161TIFF2024096766000047.tif228158TIFF2024096766000048.tif22158
[0301] SEQ ID NO:6 TIFF2024096766000049.tif200158TIFF2024096766000050.tif185159
[0302] SEQ ID NO:7 TIFF2024096766000051.tif33159TIFF2024096766000052.tif225157TIFF2024096766000053.tif127167
[0303] SEQ ID NO:8 TIFF2024096766000054.tif97166TIFF2024096766000055.tif225162TIFF2024096766000056.tif100159
[0304] SEQ ID NO:9 TIFF2024096766000057.tif121159TIFF2024096766000058.tif228157TIFF2024096766000059.tif117160
[0305] SEQ ID NO:10 TIFF2024096766000060.tif107160TIFF2024096766000061.tif227156TIFF2024096766000062.tif136161
[0306] SEQ ID NO:11 TIFF2024096766000063.tif90161TIFF2024096766000064.tif230156TIFF2024096766000065.tif228162
[0307] SEQ ID NO:12 TIFF2024096766000066.tif203166TIFF2024096766000067.tif132160
[0308] SEQ ID NO:13 TIFF2024096766000068.tif94160TIFF2024096766000069.tif230156 [ka]
[0309] SEQ ID NO:14 TIFF2024096766000071.tif198161TIFF2024096766000072.tif145163< / ar>
Claims
1. A method for analyzing the effect of a polyribonucleotide on ciliary formation, said polyribonucleotide encoding a protein related to and / or required for ciliary formation, said method comprising the steps of: (a) obtaining a nasal swab from a subject with a ciliopathic disease, the nasal swab comprising undifferentiated basal cells and differentiated ciliated cells; (b) culturing the cells obtained from step (a) as a submerged cell culture to obtain undifferentiated basal cells and dedifferentiated ciliated cells; (c) culturing the undifferentiated basal cells and dedifferentiated ciliated cells obtained from step (b) as an air-liquid interface cell culture and performing airlift; (d) transfecting the cells obtained from step (c) with a polyribonucleotide encoding a protein associated with and / or required for ciliary formation; (e) culturing the transfected cells obtained from step (d) to obtain differentiated ciliated cells; and (f) determining the effect of said polyribonucleotide on ciliary formation using lactate dehydrogenase measurement, NucGreen assay, high-speed video microscopy, ciliary beat frequency measurement, mucociliary clearance assay, and / or immunofluorescence staining.
2. The method of claim 1, wherein the cells are transfected within 0 to 48 hours after performing the airlift in step (c).
3. The cell is further provided with a polyribonucleotide encoding a protein associated with and / or required for ciliary body formation, the polyribonucleotide having the formula (V): [Formula 1] The method according to claim 1 or 2, wherein the transfection is carried out using a lipidoid having the structure shown in
4. The cells are treated in steps (b) to (e) with the following composition: [Table 1] The method according to any one of claims 1 to 3, wherein the culture medium G comprises
5. The method of any one of claims 1 to 4, wherein the nasal swab further comprises fibroblasts, and the proliferation of the fibroblasts is inhibited in steps (b) to (e).
